<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="review-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//Springer-Verlag//DTD A++ V2.4//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName A++V2.4.dtd?><?SourceDTD.Version 2.4?><?ConverterInfo.XSLTName springer2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Chin Med</journal-id><journal-id journal-id-type="iso-abbrev">Chin Med</journal-id><journal-title-group><journal-title>Chinese Medicine</journal-title></journal-title-group><issn pub-type="epub">1749-8546</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7841890</article-id><article-id pub-id-type="publisher-id">414</article-id><article-id pub-id-type="doi">10.1186/s13020-020-00414-x</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Therapeutic roles of natural remedies in combating hereditary ataxia: A systematic review</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Phang</surname><given-names>Michael Weng Lok</given-names></name><address><email>michaelphang4572@gmail.com</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Lew</surname><given-names>Sze Yuen</given-names></name><address><email>szeyuenlew@gmail.com</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Chung</surname><given-names>Ivy</given-names></name><address><email>ivychung@ummc.edu.my</email></address><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Lim</surname><given-names>William Kiong-Seng</given-names></name><address><email>kslim@unimas.my</email></address><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Lim</surname><given-names>Lee Wei</given-names></name><address><email>drlimleewei@gmail.com</email></address><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-8292-4498</contrib-id><name><surname>Wong</surname><given-names>Kah Hui</given-names></name><address><email>wkahhui@um.edu.my</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="GRID">grid.10347.31</institution-id><institution-id institution-id-type="ISNI">0000 0001 2308 5949</institution-id><institution>Department of Anatomy, Faculty of Medicine, </institution><institution>University of Malaya, </institution></institution-wrap>Kuala Lumpur, 50603 Malaysia </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="GRID">grid.10347.31</institution-id><institution-id institution-id-type="ISNI">0000 0001 2308 5949</institution-id><institution>Department of Pharmacology, Faculty of Medicine, </institution><institution>University of Malaya, </institution></institution-wrap>Kuala Lumpur, 50603 Malaysia </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="GRID">grid.412253.3</institution-id><institution-id institution-id-type="ISNI">0000 0000 9534 9846</institution-id><institution>Faculty of Medicine and Health Sciences, </institution><institution>Universiti Malaysia Sarawak, </institution></institution-wrap>Kuching, Sarawak, 94300 Malaysia </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="GRID">grid.194645.b</institution-id><institution-id institution-id-type="ISNI">0000000121742757</institution-id><institution>Neuromodulation Laboratory, School of Biomedical Sciences, Li Ka Shing Faculty of Medicine, </institution><institution>The University of Hong Kong, </institution></institution-wrap>21 Sassoon Road, Pokfulam, Hong Kong Special Administrative Region China </aff></contrib-group><pub-date pub-type="epub"><day>28</day><month>1</month><year>2021</year></pub-date><pub-date pub-type="pmc-release"><day>28</day><month>1</month><year>2021</year></pub-date><pub-date pub-type="collection"><year>2021</year></pub-date><volume>16</volume><elocation-id>15</elocation-id><history><date date-type="received"><day>27</day><month>8</month><year>2020</year></date><date date-type="rev-recd"><day>17</day><month>11</month><year>2020</year></date><date date-type="accepted"><day>11</day><month>12</month><year>2020</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2021</copyright-statement><license license-type="OpenAccess"><license-p><bold>Open Access</bold>This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p id="Par1">Hereditary ataxia (HA) represents a group of genetically heterogeneous neurodegenerative diseases caused by dysfunction of the cerebellum or disruption of the connection between the cerebellum and other areas of the central nervous system. Phenotypic manifestation of HA includes unsteadiness of stance and gait, dysarthria, nystagmus, dysmetria and complaints of clumsiness. There are no specific treatments for HA. Management strategies provide supportive treatment to reduce symptoms.</p></sec><sec><title>Objectives</title><p id="Par2">This systematic review aimed to identify, evaluate and summarise the published literature on the therapeutic roles of natural remedies in the treatment of HA to provide evidence for clinical practice.</p></sec><sec><title>Methods</title><p id="Par3">A systematic literature search was conducted using the Preferred Reporting Items for Systematic Reviews&#x000a0;and Meta-Analyses (PRISMA). Web of Science, PubMed and Science Direct Scopus were thoroughly searched for relevant published articles from June 2007 to July 2020.</p></sec><sec><title>Results</title><p id="Par4">Ten pre-clinical and two clinical studies were eligible for inclusion in this systematic review. We identified the therapeutic roles of medicinal plants <italic>Brassica napus, Gardenia jasminoides, Gastrodia elata, Ginkgo biloba, Glycyrrhiza inflata, Paeonia lactiflora, Pueraria lobata</italic> and <italic>Rehmannia glutinosa</italic>; herbal formulations Shaoyao Gancao Tang and Zhengan Xifeng Tang; and medicinal mushroom <italic>Hericium erinaceus</italic> in the treatment of HA. In this review, we evaluated the mode of actions contributing to their therapeutic effects, including activation of the ubiquitin&#x02013;proteasome system, activation of antioxidant pathways, maintenance of intracellular calcium homeostasis and regulation of chaperones. We also briefly highlighted the integral cellular signalling pathways responsible for orchestrating the mode of actions.</p></sec><sec><title>Conclusion</title><p id="Par5">We reviewed the therapeutic roles of natural remedies in improving or halting the progression of HA, which warrant further study for applications into clinical practice.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Hereditary ataxia</kwd><kwd>Natural remedy</kwd><kwd>Medicinal plant</kwd><kwd>Herbal formulation</kwd><kwd>Medicinal mushroom</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100004386</institution-id><institution>Universiti Malaya</institution></institution-wrap></funding-source><award-id>GPF003C-2019</award-id></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2021</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Background</title><p id="Par43">Ataxia is defined as the loss of full control of bodily movements, and can be inherited, acquired, or occur sporadically [<xref ref-type="bibr" rid="CR1">1</xref>]. Hereditary ataxia (HA) represents a group of genetically heterogeneous neurodegenerative diseases resulting from dysfunction of the cerebellum or disruption of connection between the cerebellum and other areas of the central nervous system [<xref ref-type="bibr" rid="CR2">2</xref>]. Hereditary ataxia is characterised by pyramidal syndrome, movement disorder, seizure, peripheral neuropathy and cognitive dysfunction [<xref ref-type="bibr" rid="CR3">3</xref>]. Furthermore, HA patients often present with unsteadiness of stance and gait, dysarthria, nystagmus, dysmetria and clumsiness [<xref ref-type="bibr" rid="CR4">4</xref>]. Classification of the subtypes of HA is very challenging due to the many neurological and metabolic diseases associated with cerebellar dysfunction, and the phenotypic heterogeneity among the hereditary disorders [<xref ref-type="bibr" rid="CR5">5</xref>]. Nevertheless, HA can be classified by the pattern of inheritance: autosomal dominant, autosomal recessive and X-linked ataxia [<xref ref-type="bibr" rid="CR3">3</xref>].</p><p id="Par44">Among the autosomal dominant cerebellar ataxias (ADCA), spinocerebellar ataxia (SCA) 3 is the most common subtype, followed by SCA1, 2, 6, 7 and 17, which are all caused by the expansion of polyglutamine-coding Cytosine-Adenine-Guanine (CAG) repeats [<xref ref-type="bibr" rid="CR6">6</xref>]. Another ACDA subtype is episodic ataxia (EA), which include the common EA1 and 2 subtypes [<xref ref-type="bibr" rid="CR2">2</xref>]. Among the autosomal recessive cerebellar ataxias (ARCA), Friedreich&#x02019;s ataxia (FRDA) is the most common subtype, followed by ataxia-telangiectasia (AT), and ataxia oculomotor apraxia type 1 (AOA1) and type 2 (AOA2) [<xref ref-type="bibr" rid="CR7">7</xref>]. The most common X-linked ataxia is fragile X-associated tremor ataxia syndrome (FXTAS). The age of onset varies according to types of HA, but onset actually helps in the diagnosis of HA: infancy onset suggests AT; childhood or teenage onsets suggest EA, FRDA, AOA1 and AOA2; and adult onset suggests SCA, FXTAS, or other autosomal recessive cerebellar ataxias [<xref ref-type="bibr" rid="CR5">5</xref>]. Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref> summarises the highly prevalent types of HA and their specific ethnic distributions, gene and locus of mutation, and clinical presentations.<table-wrap id="Tab1"><label>Table&#x000a0;1</label><caption><p>Common forms of hereditary ataxia (HA)</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2">Hereditary ataxia</th><th align="left" rowspan="2">Ethnicity</th><th align="left" rowspan="2">Gene and locus of mutation</th><th align="left" colspan="2">Clinical presentation</th><th align="left" rowspan="2">Neuroimaging finding</th><th align="left" rowspan="2">Neurometabolite finding</th><th align="left" rowspan="2">Biochemical finding</th><th align="left" rowspan="2">Reference</th></tr><tr><th align="left">Motor symptom</th><th align="left">Non-motor symptom</th></tr></thead><tbody><tr><td align="left" colspan="9">Autosomal dominant</td></tr><tr><td align="left">&#x000a0;SCA1</td><td align="left">Russian, Polish, Indian, Japanese and Eastern Siberian</td><td align="left">ATXN1 on chromosome 6p22.3</td><td align="left">Gait ataxia, pyramidal, extrapyramidal and bulbar signs, dysarthria, nystagmus, chorea and peripheral neuropathy</td><td align="left">Cognitive impairment and respiratory failure</td><td align="left">Atrophy of the cerebellum, brainstem and cerebral frontal lobe</td><td align="left"><p>Decreased glutamate, tNAA, NAA/Cr ratio and Cho/Cr ratio</p><p>Increased glutamine, myoinositol and tCr</p></td><td align="left">Increased lactate</td><td align="left">[<xref ref-type="bibr" rid="CR6">6</xref>&#x02013;<xref ref-type="bibr" rid="CR12">12</xref>]</td></tr><tr><td align="left">&#x000a0;SCA2</td><td align="left">Cuban, Korean, South African and Indian</td><td align="left">ATXN2 on chromosome 12q24.12</td><td align="left">Gait ataxia, pyramidal and extrapyramidal signs, dysarthria and dysphagia</td><td align="left">Cognitive impairment, psychiatric symptoms, sleep disturbances and slow saccadic eye movements</td><td align="left">Atrophy of cerebellum, brainstem, cerebral frontal lobe, spinal cord and cranial nerves III to XII</td><td align="left"><p>Decreased glutamate, tNAA, NAA/Cr ratio and Cho/Cr ratio</p><p>Increased myoinositol and tCr</p></td><td align="left"><p>Decreased GSH, GST, SOD, CAT, zinc, iron, copper, erythropoietin, dopamine metabolites and ethanolamine</p><p>Increased MDA</p></td><td align="left">[<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR8">8</xref>&#x02013;<xref ref-type="bibr" rid="CR14">14</xref>]</td></tr><tr><td align="left">&#x000a0;SCA3/MJD</td><td align="left"><p>Portuguese, Japanese,</p><p>Taiwanese,</p><p>German and Brazilian</p></td><td align="left">ATXN3 on chromosome 14q32.12</td><td align="left">Gait ataxia, pyramidal and extrapyramidal signs, nystagmus, lid retraction, decreased saccade velocity, amyotrophy fasciculations and peripheral neuropathy</td><td align="left">Mild cognitive impairment, sleep disturbances and involuntary weight loss</td><td align="left">Atrophy of cerebellum, brainstem, cerebellar peduncle and cranial nerves III to XII</td><td align="left"><p>Decreased glutamate, tNAA, NAA/Cr ratio, Cho/Cr ratio, tNAA/tCr ratio and Glx/tCr ratio</p><p>Increased myoinositol and tCr</p></td><td align="left"><p>Decreased GPx, <sc>l</sc>-Proline and <sc>l</sc>-Tryptophan</p><p>Increased palmitoleic acid (FFA 16:1) and linolenic acid (FFA 18:3)</p></td><td align="left">[<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR9">9</xref>&#x02013;<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR15">15</xref>&#x02013;<xref ref-type="bibr" rid="CR17">17</xref>]</td></tr><tr><td align="left">&#x000a0;SCA6</td><td align="left">Japanese, American, German, Australian and Dutch</td><td align="left">CACNA1A on chromosome 19p13.13</td><td align="left">Gait ataxia, pyramidal signs, dysarthria, nystagmus, intention tremor, dystonia and dysphagia</td><td align="left">Diplopia</td><td align="left">Atrophy of cerebellum</td><td align="left"><p>Decreased NAA and NAA/Cr ratio</p><p>Increased myoinositol</p></td><td align="left">Increased glucose, taurine and lactate</td><td align="left">[<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR10">10</xref>&#x02013;<xref ref-type="bibr" rid="CR12">12</xref>]</td></tr><tr><td align="left">&#x000a0;SCA7</td><td align="left">South African, Mexican and Scandinavian</td><td align="left">ATXN7 on chromosome 3p14.1</td><td align="left">Gait ataxia, pyramidal signs, slow eye movements, dysmetria, hyperreflexia, dysarthria, dysphagia and ophthalmoplegia</td><td align="left">Visual loss with retinopathy, cognitive impairment and psychiatric symptoms</td><td align="left">Atrophy of cerebellum, brainstem, cerebral peduncle and spinal cord</td><td align="left"><p>Decreased glutamate and tNAA</p><p>Increased myoinositol and tCr</p></td><td align="left">Increased lipid hydroperoxides, MDA, protein carbonyls, GR, GPx and paraoxonase</td><td align="left">[<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR9">9</xref>&#x02013;<xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR19">19</xref>]</td></tr><tr><td align="left">&#x000a0;SCA17/HDL4</td><td align="left">Japanese, German and Italian</td><td align="left">TBP on chromosome 6q27</td><td align="left">Gait ataxia, pyramidal and extrapyramidal signs, chorea and myoclonus</td><td align="left">Cognitive impairment and psychiatric symptoms</td><td align="left">Atrophy in cerebellum, brainstem and cerebrum</td><td align="left">N/A</td><td align="left">Decreased presynaptic dopamine transporters</td><td align="left">[<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR20">20</xref>, <xref ref-type="bibr" rid="CR21">21</xref>]</td></tr><tr><td align="left">&#x000a0;EA1</td><td align="left">Australian, Caucasian, American and Russian</td><td align="left">KCNA1 on chromosome 12p13</td><td align="left">Gait ataxia (attack last from seconds to minutes), dysarthria, seizure, myokymia, neuromyotonic and tremor</td><td align="left">Vertigo, difficulty in breathing and diaphoresis</td><td align="left">Normal brain</td><td align="left">N/A</td><td align="left">Increased GABA release</td><td align="left">[<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR22">22</xref>&#x02013;<xref ref-type="bibr" rid="CR24">24</xref>]</td></tr><tr><td align="left">&#x000a0;EA2</td><td align="left">Caucasian and Korean</td><td align="left">CACNA1A on chromosome 19p13</td><td align="left">Gait ataxia (attack last from minutes to hours), dysarthria, seizure, nystagmus and dystonia</td><td align="left">Vertigo, nausea, headache, diplopia, tonic upward gaze and cognitive impairment</td><td align="left">Atrophy of cerebellum</td><td align="left">Decreased Cr and high-energy phosphate ratio</td><td align="left">Increased lactate</td><td align="left">[<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR22">22</xref>, <xref ref-type="bibr" rid="CR23">23</xref>, <xref ref-type="bibr" rid="CR25">25</xref>, <xref ref-type="bibr" rid="CR26">26</xref>]</td></tr><tr><td align="left" colspan="9">Autosomal recessive</td></tr><tr><td align="left">&#x000a0;FRDA</td><td align="left">Caucasian, Middle East and North African</td><td align="left">FXN on chromosome 9q21.11</td><td align="left">Gait ataxia, eye movement abnormalities, dysarthria, dysphagia, lower extremities weakness and peripheral neuropathy</td><td align="left">Skeletal deformities, hypertrophic cardiomyopathy, diabetes, deafness and optic atrophy</td><td align="left">Atrophy of cerebellum and cervical spinal cord</td><td align="left"><p>Decreased NAA/Cr ratio and Cho</p><p>Increased glutamine, myoinositol and tCr</p></td><td align="left">N/A</td><td align="left">[<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR27">27</xref>, <xref ref-type="bibr" rid="CR28">28</xref>]</td></tr><tr><td align="left">&#x000a0;AT</td><td align="left">Iberian, Polish and Russian</td><td align="left">ATM on chromosome 11q22.3</td><td align="left"><p>Gait ataxia, extrapyramidal signs,</p><p>oculomotor apraxia, hypotonia, areflexia and peripheral neuropathy</p></td><td align="left">Oculocutaneous telangiectasia, immunodeficiency, cancer susceptibility, sterility, extreme radio sensitivity, diabetes and pulmonary diseases</td><td align="left">Atrophy of cerebellum and brainstem</td><td align="left"><p>Decreased NAA, Cho, NAA/Cho ratio and Cr</p><p>Increased Cho and Cho/Cr ratio</p></td><td align="left"><p>Decreased IgA, IgM, IgG2, IgE and absence of ATM protein</p><p>Increased AFP</p></td><td align="left">[<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR29">29</xref>&#x02013;<xref ref-type="bibr" rid="CR31">31</xref>]</td></tr><tr><td align="left">&#x000a0;AOA1</td><td align="left">Japanese and Portuguese</td><td align="left">APTX on chromosome 9p21.1</td><td align="left">Gait ataxia, extrapyramidal signs, oculomotor apraxia, areflexia, dysarthria, choreoathetosis, oculomotor apraxia and peripheral neuropathy</td><td align="left">Cognitive impairment and skeletal deformities</td><td align="left">Atrophy of cerebellum</td><td align="left">N/A</td><td align="left"><p>Decreased albumin level</p><p>Increased creatine kinase and total cholesterol</p></td><td align="left">[<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR32">32</xref>, <xref ref-type="bibr" rid="CR33">33</xref>]</td></tr><tr><td align="left">&#x000a0;AOA2</td><td align="left">Eastern French</td><td align="left">SETX on chromosome 9p34.13</td><td align="left">Gait ataxia, pyramidal and extrapyramidal signs, oculomotor apraxia, chorea, upper motor neuron signs, head tremor, strabismus and peripheral neuropathy</td><td align="left">Mild cognitive impairment</td><td align="left">Atrophy of cerebellum</td><td align="left"><p>Decreased glutamate, NAA and NAA/Cho ratio</p><p>Increased myoinositol</p></td><td align="left">Increased creatinine kinase, total cholesterol, AFP, IgG and IgA</td><td align="left">[<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR32">32</xref>, <xref ref-type="bibr" rid="CR34">34</xref>]</td></tr><tr><td align="left" colspan="9">X-linked</td></tr><tr><td align="left">&#x000a0;FXTAS</td><td align="left">Caucasian</td><td align="left">FMR1 on X chromosome</td><td align="left">Gait ataxia, intention tremor, eye movement abnormalities and peripheral neuropathy</td><td align="left">Cognitive impairment, psychiatric symptoms, hearing loss and dysautonomia</td><td align="left">Atrophy of cerebellum and cerebrum</td><td align="left">Decreased NAA</td><td align="left">N/A</td><td align="left">[<xref ref-type="bibr" rid="CR35">35</xref>&#x02013;<xref ref-type="bibr" rid="CR37">37</xref>]</td></tr></tbody></table><table-wrap-foot><p><italic>AFP</italic> alpha fetoprotein, <italic>AOA</italic> ataxia oculomotor apraxia, <italic>AT</italic> ataxia-telangiectasia, <italic>Cho</italic> choline compounds, <italic>Cr</italic> creatine, <italic>EA</italic> episodic ataxia, <italic>FRDA</italic> Friedreich&#x02019;s ataxia, <italic>FXTAS</italic> fragile X tremor-ataxia syndrome, <italic>GABA</italic> &#x003b3;-aminobutyric acid, <italic>Glx</italic> glutamate&#x02009;+&#x02009;glutamine, <italic>GST</italic> glutathione S-transferase, <italic>GPx</italic> glutathione peroxidase, <italic>GR</italic> glutathione reductase, <italic>GSH</italic> glutathione, <italic>HDL4</italic> Huntington disease-like 4, <italic>Ig</italic> immunoglobulin, <italic>MDA</italic> malondialdehyde, <italic>MJD</italic> Machado-Joseph disease, <italic>N/A</italic> not applicable, <italic>NAA N</italic>-acetylaspartate, <italic>NAAG N</italic>-acetylaspartatylglutamate, <italic>PCr</italic> phosphocreatine, <italic>SOD</italic> superoxide distmutase, <italic>SCA</italic> spinocerebellar ataxia, <italic>tCr</italic> total creatine (Cr&#x02009;+&#x02009;PCr), <italic>tNAA</italic> total NAA (NAA&#x02009;+&#x02009;NAAG)</p></table-wrap-foot></table-wrap></p><p id="Par45">Generally, HA is first diagnosed by assessing the history of the presenting condition, past medical history, and personal history, and then by neurological evaluation, systemic physical evaluation, and pertinent paraclinical tests. Laboratory tests can rule out acquired ataxia and identify biomarkers specific to the HA. Neuroimaging using magnetic resonance imaging (MRI) and computed tomography (CT) are useful to determine the presence of cerebellar atrophy or anomalies. After excluding acquired ataxia, the mode of inheritance is then evaluated. In this context, the age of onset and clinical manifestation can well-describe the HA and may provide crucial clue(s) to identify the mutated gene. Molecular genetic testing for HA with high prevalence such as SCA and FRDA is usually suggested before pursuing other extensive tests [<xref ref-type="bibr" rid="CR21">21</xref>]. If single gene testing does not provide a molecular diagnosis, then high-throughput next-generation sequencing (NGS) such as multigene panel testing, whole-exome or whole-genome sequencing can be conducted to identify the mutated genes. Specialised genetic counselling and risk assessment can then be provided once the pathogenic mutation has been identified [<xref ref-type="bibr" rid="CR5">5</xref>].</p><p id="Par46">To date, there are no effective treatments for HA and current therapeutic strategies only focus on symptomatic and supportive management [<xref ref-type="bibr" rid="CR38">38</xref>]. The complexity in the neurochemistry of HA suggests that there may be multiple therapeutic targets. For example, some pharmacological molecules have been used to target motor and non-motor symptoms associated with HA [<xref ref-type="bibr" rid="CR39">39</xref>]: riluzole, amantadine and varenicline were demonstrated to reduce the deteriorating symptoms in various ADCA and ARCA [<xref ref-type="bibr" rid="CR4">4</xref>]; acetazolamide and 4-aminopyridine (4-AP) were reported to be effective in reducing symptoms in EA; and acetyl-DL-leucine was found to improve gait variability in patients with various subtypes of cerebellar ataxia including SCA [<xref ref-type="bibr" rid="CR40">40</xref>]. N-acetyl-L-leucine is currently being tested in a multinational clinical trial as a treatment for AT [<xref ref-type="bibr" rid="CR41">41</xref>]. Nevertheless, many pharmacological molecules have yet to reach clinical trials or be translated into breakthrough treatments, mainly due to the limited pre-clinical studies [<xref ref-type="bibr" rid="CR6">6</xref>]. More efforts are needed to discover safe therapeutic agents for HA [<xref ref-type="bibr" rid="CR42">42</xref>].</p><p id="Par47">Natural remedies have been used as complementary therapeutic agents for various neurodegenerative diseases [<xref ref-type="bibr" rid="CR43">43</xref>, <xref ref-type="bibr" rid="CR44">44</xref>]. Natural remedies are a good source for the discovery of drugs or agents that have therapeutic potential. In addition, holistic practitioners commonly use natural remedies, as they are well accepted and relatively safe compared to synthetic drugs. One of&#x000a0;the&#x000a0;key distinguishing attributes of natural remedies is&#x000a0;their affinity for the target protein or specific biomolecule in living organisms [<xref ref-type="bibr" rid="CR44">44</xref>]. The distinct features of biological compounds including more chiral centres; more carbon, hydrogen and oxygen and less nitrogen; higher molecular weight and higher polarities compared to synthetic compounds [<xref ref-type="bibr" rid="CR45">45</xref>]. Biological compounds also contain more sp<sup>3</sup>-hybrid carbon atoms allowing the tetrahedron carbons to form flexible chains or cyclic structures, whereas the multi-functional groups make them bind to the biological targets strongly and increase the additional interactions with biological molecules [<xref ref-type="bibr" rid="CR46">46</xref>]. Natural metabolites with greater structural diversity, bioactivity and complexity are capable of becoming the substrate for one or more of the transporter systems and to be delivered to the targeted intracellular site of action [<xref ref-type="bibr" rid="CR47">47</xref>].</p><p id="Par48">Besides, with the recent shift in the mode of discovery from &#x0201c;one-target, one-drug&#x0201d; to &#x0201c;network-target, multiple-component-therapeutics&#x0201d;, many natural remedies or compounds with broad safety profiles have great potential as they have proven efficacy on multiple targets in different diseases [<xref ref-type="bibr" rid="CR48">48</xref>]. The concept of multiple-target compounds involves the merging of active substructures or the fusion of two or more biological active moieties into one compound in the enhancement of biological activities [<xref ref-type="bibr" rid="CR49">49</xref>]. Curcumin, resveratrol, quercetin, green tea catechins and salicylate are some of the well-studied biological compounds with multiple molecular targets and mechanism of action elucidated [<xref ref-type="bibr" rid="CR50">50</xref>]. However, a disadvantage of biological compounds with multiple targets is the ability to bind to multiple proteins of unrelated structures or the unintended off-targets, which may result in potential toxicity and adverse effects [<xref ref-type="bibr" rid="CR51">51</xref>]. Therefore, it is crucial to characterise and optimise the structure of biological compounds to boost their affinity against the disease-related targets and weaken the activity towards undesired adverse targets [<xref ref-type="bibr" rid="CR50">50</xref>].</p><p id="Par49">Chinese medicines or traditional Chinese medicines (TCM) have a long history of use in Chinese communities in East and Southeast Asia since ancient times. The basic concepts of TCM originated from the ancient naturalistic philosophies namely <italic>qi</italic>, <italic>yin yang</italic> and the five phases (<italic>wu xing</italic>) theory included wood (<italic>mu</italic>), fire (<italic>huo</italic>), earth (<italic>tu</italic>), metal (<italic>jin</italic>) and water (<italic>shui</italic>) [<xref ref-type="bibr" rid="CR52">52</xref>]. TCM is a holistic approach as it focuses on the integrity of the human body and its close relationship with social and natural environment. Numerous natural therapeutic methods such as mind-spiritual methods (<italic>qi gong</italic> and <italic>tai chi</italic>) and natural methods (acupuncture, moxibustion and herbal medicine) were applied in TCM to maintain overall health and enhance body&#x02019;s resistance to disease. The accumulation of empirical experience and collection of observational data in clinical settings are responsible in the development of TCM over the centuries [<xref ref-type="bibr" rid="CR53">53</xref>].</p><p id="Par50">Demand for TCM continues to grow in the Western world. Application of modern disciplines in TCM has resulted in the isolation and identification of novel and/or active compounds. Some of these were developed to produce new drugs for the treatment of important diseases such as malaria, vascular diseases and cancer which is deemed necessary to improve the quality of TCM materials. However, a majority of TCM has not been elucidated chemically and pharmacologically and most of the TCM-derived compounds were found not to be as active as the original TCM preparation. This points to the possibilities of synergism being involved [<xref ref-type="bibr" rid="CR48">48</xref>]. Herbal formulation that contains two or more herbs in specific proportions have been used to treat a variety of symptoms in a wide range of diseases, such as forgetfulness, disorientation, insomnia, unconsciousness, cramps and seizures [<xref ref-type="bibr" rid="CR54">54</xref>].</p><p id="Par51">Therefore, it is a challenging task to develop evidence-based Chinese medicine and new lead compounds and scaffolds from TCM. Combined chemical and biological studies on the effective TCM have provided unprecedented opportunities for the development of new drugs and the modernisation of TCM. In such circumstances, many in vitro and in vivo studies have been conducted to explore the therapeutic effect of the natural remedies in HA. However, the therapeutic efficacy of these natural remedies has yet to be demonstrated or translated into clinical practice. Hence, this review aims to synthesise the evidence in pre-clinical and clinical research on natural remedies published from June 2007 to July 2020 to examine if these experimental studies may provide a mechanistic framework for developing treatments for HA towards clinical trials.</p></sec><sec id="Sec2"><title>Methods</title><sec id="Sec3"><title>Search strategy</title><p id="Par52">We conducted a systematic search of Web of Science, PubMed and Science Direct Scopus electronic databases for relevant articles published from June 2007 to July 2020. Google Scholar was used to identify any articles not included in the above databases. The search terms included a combination of the following keywords: algae, alternative medicine, ataxia, basidiomycete, complementary medicine, herbal, herbs, medicinal plants, medicinal mushrooms, mushrooms, natural products, plants and seaweed. The structured search strategy was designed to include all papers that evaluated the use of natural remedies as a treatment for HA published from June 2007 to July 2020.</p></sec><sec id="Sec4"><title>Eligibility criteria</title><p id="Par53">Studies were considered if they met the following inclusion criteria: (1) pre-clinical (in vitro and in vivo studies) and clinical studies, (2) study model of HA as the primary disorder, (3) full-text available and (4) articles published in English. The exclusion criteria included: (1) studies with ataxia as the secondary symptom, (2) studies targeting non-motor symptoms, (3) studies using chemicals to induce ataxia, (4) review articles, (5) conference abstracts or proceedings, (6) full-text not available and (7) articles published in another language other than English.</p></sec><sec id="Sec5"><title>Data extraction and analysis</title><p id="Par54">Collection and extraction of data were conducted according to the Preferred Reporting Items for Systematic Review and Meta-Analyses (PRISMA). Two researchers (M.W.L.P and S.Y.L) searched and independently reviewed all the relevant studies and selected the ones meeting the inclusion criteria. Disagreements on the eligibility or on the extraction of data were resolved through discussions between the two researchers. The other team members made the final decision if the two researchers could not reach an agreement. Due to inconsistencies in the methodology or experimental design in the retrieved studies, findings were extracted independently and narrated to the best of our ability.</p></sec></sec><sec id="Sec6"><title>Results</title><sec id="Sec7"><title>Study selection</title><p id="Par55">The systematic literature search yielded 3113 results from the three databases. After eliminating duplicate studies, 1829 studies remained and were further evaluated by screening the titles and abstracts. The full-texts of 18 selected studies were retrieved for further assessment and evaluation. Six articles were excluded at this stage for various reasons including language, study design, not ataxia-specific, or ataxia was a secondary symptom. Overall, 12 studies (ten pre-clinical studies and two clinical studies) were eligible for inclusion in this systematic review. Figure&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref> shows the PRISMA flow chart for the identification of relevant studies.<fig id="Fig1"><label>Fig.&#x000a0;1</label><caption><p>PRISMA flowchart for identification of relevant studies</p></caption><graphic xlink:href="13020_2020_414_Fig1_HTML" id="MO1"/></fig></p><p id="Par56">Based on the retrieved studies, we found several natural remedies, including medicinal plants, herbal formulations and medicinal mushrooms, had been investigated as treatments in only two subtypes of HA, SCA and FRDA. The list of natural remedies and their bioactive effects against HA are summarised in Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>. The chemical constituents of the identified natural remedies&#x000a0;are shown in Fig. <xref rid="Fig2" ref-type="fig">2</xref>; namely the catalpol (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>a) from <italic>Rehmannia glutinosa</italic>; puerarin (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>b) and daidzein (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>c) from <italic>Pueraria lobata</italic>; genipin (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>d), geniposide (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>e) and crocin (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>f) from <italic>Gardenia jasminoides</italic>; licochalcone A (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>g) and ammonium glycyrrhizinate (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>h) from <italic>Glycyrrhiza inflata</italic>; sinapine (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>i) in rapeseed pomace; and paeoniflorin (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>j) from <italic>Paeonia lactiflora</italic>; and T1-11 (N<sup>6</sup>-(4-Hydroxybenzyl) adenosine) (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>k) and JMF-1907 (N<sup>6</sup>-(3-Indolylethyl) adenosine) (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>l) from <italic>Gastrodia elata.</italic></p><p>
<table-wrap id="Tab2"><label>Table&#x000a0;2</label><caption><p>Natural remedies and their therapeutic effects</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Disorder</th><th align="left">Natural Remedies</th><th align="left">Compounds</th><th align="left">Model</th><th align="left">Finding</th><th align="left">Mode of Action</th><th align="left">Reference</th></tr></thead><tbody><tr><td align="left" colspan="7">Medicinal plant</td></tr><tr><td align="left" rowspan="7">&#x000a0;SCA3</td><td align="left"><p><italic>Rehmannia glutinosa</italic></p><p>
<inline-graphic xlink:href="13020_2020_414_Figa_HTML.gif" id="d32e1612"/></p></td><td align="left">Catalpol</td><td align="left">HEK-293 and SH-SY5Y cells</td><td align="left">Promoted proteasome activity, suppressed polyQ aggregation, prevented cell death</td><td align="left" rowspan="3">UPS</td><td align="left">[<xref ref-type="bibr" rid="CR55">55</xref>]</td></tr><tr><td align="left"><p><italic>Pueraria lobate</italic></p><p>
<inline-graphic xlink:href="13020_2020_414_Figb_HTML.gif" id="d32e1639"/></p></td><td align="left">Puerarin and daidzein</td><td align="left">iPSCs</td><td align="left">Promoted proteasome activity, suppressed polyQ aggregation, prevented cell death</td><td align="left">[<xref ref-type="bibr" rid="CR56">56</xref>]</td></tr><tr><td align="left"><p><italic>Gastrodia elata</italic></p><p>
<inline-graphic xlink:href="13020_2020_414_Figc_HTML.gif" id="d32e1663"/></p></td><td align="left">T1-11 and JMF-1907</td><td align="left">Mice</td><td align="left">Promoted proteasome activity, prevented cell death, restored motor function</td><td align="left">[<xref ref-type="bibr" rid="CR57">57</xref>]</td></tr><tr><td align="left"><p><italic>Gardenia jasminoides</italic></p><p>
<inline-graphic xlink:href="13020_2020_414_Figd_HTML.gif" id="d32e1687"/></p></td><td align="left">Genipin, geniposide and crocin</td><td align="left" rowspan="3">HEK-293 and SH-SY5Y cells</td><td align="left">Promoted the expression of antioxidant genes, suppressed ROS level</td><td align="left" rowspan="2">NRF2 signalling pathway</td><td align="left">[<xref ref-type="bibr" rid="CR58">58</xref>]</td></tr><tr><td align="left"><p><italic>Glycyrrhiza inflata</italic></p><p>
<inline-graphic xlink:href="13020_2020_414_Fige_HTML.gif" id="d32e1714"/></p></td><td align="left">Licochalcone A and AMGZ</td><td align="left">Promoted the expression of antioxidant genes, suppressed ROS level, suppressed polyQ aggregation</td><td align="left">[<xref ref-type="bibr" rid="CR59">59</xref>]</td></tr><tr><td align="left"><p><italic>Paeonia lactiflora</italic></p><p>
<inline-graphic xlink:href="13020_2020_414_Figf_HTML.gif" id="d32e1735"/></p></td><td align="left">Paeoniflorin</td><td align="left">Promoted expression of heat shock proteins, suppressed polyQ aggregation, restored motor function</td><td align="left">N/A</td><td align="left">[<xref ref-type="bibr" rid="CR60">60</xref>]</td></tr><tr><td align="left"><p><italic>Brassica napus</italic></p><p>
<inline-graphic xlink:href="13020_2020_414_Figg_HTML.gif" id="d32e1759"/></p></td><td align="left">Sinapine</td><td align="left">Roundworm</td><td align="left">Promoted expression of antioxidant genes, suppressed ROS level, restored motor function</td><td align="left">N/A</td><td align="left">[<xref ref-type="bibr" rid="CR61">61</xref>]</td></tr><tr><td align="left">SCA17</td><td align="left"><p><italic>Ginkgo biloba</italic></p><p>
<inline-graphic xlink:href="13020_2020_414_Figh_HTML.gif" id="d32e1789"/></p></td><td align="left">N/A</td><td align="left">SH-SY5Y cells and mice</td><td align="left">Prevented calcium influx, prevented cell death</td><td align="left">Calcium homeostasis</td><td align="left">[<xref ref-type="bibr" rid="CR62">62</xref>]</td></tr><tr><td align="left" colspan="7">Herbal formulation</td></tr><tr><td align="left">&#x000a0;SCA6</td><td align="left">Zhengan Xifeng Tang</td><td align="left">N/A</td><td align="left">Human</td><td align="left">Restored motor function</td><td align="left">N/A</td><td align="left">[<xref ref-type="bibr" rid="CR63">63</xref>, <xref ref-type="bibr" rid="CR64">64</xref>]</td></tr><tr><td align="left">&#x000a0;SCA17</td><td align="left">Shaoyao Gancao Tang</td><td align="left">N/A</td><td align="left">HEK-293 and SH-SY5Y cells</td><td align="left">Promoted expression of antioxidant genes, prevented cell death, restored mitochondrial biogenesis, restored motor function</td><td align="left">N/A</td><td align="left">[<xref ref-type="bibr" rid="CR65">65</xref>]</td></tr><tr><td align="left" colspan="7">Medicinal mushroom</td></tr><tr><td align="left">&#x000a0;FRDA</td><td align="left"><p><italic>Hericium erinaceus</italic></p><p>
<inline-graphic xlink:href="13020_2020_414_Figi_HTML.gif" id="d32e1881"/></p></td><td align="left">N/A</td><td align="left">Fibroblast</td><td align="left">Prevented antioxidant depletion, prevented cell death</td><td align="left">N/A</td><td align="left">[<xref ref-type="bibr" rid="CR66">66</xref>]</td></tr></tbody></table><table-wrap-foot><p><italic>SCA</italic> spinocerebellar ataxia, <italic>HEK-293</italic> human embryonic kidney 293 cells, <italic>UPS</italic> ubiquitin&#x02013;proteasome system, <italic>iPSCs</italic> induced-pluripotent stem cells, T1-11, N<sup>6</sup>-(4-Hydroxybenzyl) adenosine; JMF-1907, N<sup>6</sup>-(3-Indolylethyl) adenosine; <italic>NRF2</italic> nuclear factor erythroid 2&#x02013;related factor 2; <italic>AMGZ</italic> ammonium glycyrrhizinate; <italic>FRDA</italic> Friedreich&#x02019;s ataxia; <italic>N/A</italic> not applicable</p></table-wrap-foot></table-wrap></p><p id="Par100"><fig id="Fig2"><label>Fig.&#x000a0;2</label><caption><p>Chemical structures of the identified compounds with bioactive effects against HA</p></caption><graphic xlink:href="13020_2020_414_Fig2_HTML" id="MO2"/></fig></p></sec></sec><sec id="Sec8"><title>Discussion</title><sec id="Sec9"><title>Mode of action</title><sec id="Sec10"><title>Activation of ubiquitin&#x02013;proteasome system (UPS)</title><p id="Par57">In SCA, abnormal expansion of CAG repeats in respective coding regions of SCA leads to elongated translation of the polyglutamine (polyQ) tract. When the expansion reaches a specific threshold, it causes the abnormal configuration of the encoded polyQ protein, leading to protein aggregation and nuclear inclusions, a pathological hallmark of SCA [<xref ref-type="bibr" rid="CR67">67</xref>]. The presence of polyQ aggregates are detrimental to cellular processes, and contributes to cellular dysfunction and death [<xref ref-type="bibr" rid="CR68">68</xref>, <xref ref-type="bibr" rid="CR69">69</xref>]. The UPS plays a pivotal role in intracellular protein homeostasis by clearing misfolded and defective proteins [<xref ref-type="bibr" rid="CR69">69</xref>]. Furthermore, UPS is one of the major regulators of cell cycle progression and apoptosis [<xref ref-type="bibr" rid="CR70">70</xref>]. Evidence shows polyQ proteins are susceptible to ubiquitination and proteasome degradation [<xref ref-type="bibr" rid="CR71">71</xref>&#x02013;<xref ref-type="bibr" rid="CR74">74</xref>]. However, it was shown that the accumulation of polyQ aggregates compromised the function of UPS in SCA [<xref ref-type="bibr" rid="CR55">55</xref>&#x02013;<xref ref-type="bibr" rid="CR57">57</xref>] potentially through deubiquitylation [<xref ref-type="bibr" rid="CR66">66</xref>], leading to further accumulation of aggregates that would otherwise have been removed. Therefore, restoration of UPS function using natural remedies may serve as a therapeutic strategy against polyQ-induced SCA.</p><p id="Par58">In a study by Chen et al. [<xref ref-type="bibr" rid="CR55">55</xref>], the anti-aggregation effects of catalpol derived from <italic>Rehmannia glutinosa</italic>, and daidzein and puerarin derived from <italic>Pueraria lobata</italic> were investigated in in vitro models of SCA3. Carbobenzoxy-L-leucyl-L-leucyl-L-leucinal (MG132), a proteasome inhibitor, was used to treat human embryonic kidney 293 cells (HEK-293) and neuroblastoma SH-SY5Y cells expressing mutant ataxin-3 proteins. Pre-treatment with 0.1&#x000a0;&#x003bc;M catalpol, puerarin or daidzein for 24&#x000a0;h showed no cytotoxicity against the cells, as indicated by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay. The compounds were able to restore UPS function and effectively enhance proteasome activity in the cells, as evidenced by low green fluorescent protein (GFP) intensity. Additionally, the compounds suppressed polyQ aggregation induced by mutant ataxin-3 protein, as detected by Western blot analysis. Following pre-treatment with the test compounds, no autophagy activity was observed in the cells, as evidenced by an insignificant increase in red fluorescent protein (DsRed-LC3) intensity, suggesting the anti-aggregation ability of the compounds were due to UPS activation. Furthermore, the compounds also suppressed the expression of pro-apoptotic marker BCL-2-associated X (BAX) protein and promoted the expression of anti-apoptotic marker B-cell lymphoma 2 (BCL2) protein. Caspase-3 activity was also reduced, which prevented polyQ-induced cell death [<xref ref-type="bibr" rid="CR55">55</xref>]. These findings were in line with another study by Chen et al. [<xref ref-type="bibr" rid="CR56">56</xref>] using an in vitro model of SCA3 with MG132-induced pluripotent stem cells (iPSCs). Pre-treatment with 50&#x000a0;&#x003bc;M daidzein for 24&#x000a0;h restored proteasome activity in the cells. Additionally, daidzein was able to suppress MG132-induced cell death, as indicated by lactate dehydrogenase (LDH) assay [<xref ref-type="bibr" rid="CR56">56</xref>].</p><p id="Par59">A study by Chou et al. [<xref ref-type="bibr" rid="CR57">57</xref>] investigated the proteasome enhancing ability of T1-11 (N<sup>6</sup>-(4-Hydroxybenzyl) adenosine), a compound derived from <italic>Gastrodia elata</italic>, and JMF-1907 (N<sup>6</sup>-(3-Indolylethyl) adenosine), a synthetic analogue of the former. They used an in vivo model of SCA3 in transgenic mice expressing mutant ataxin-3 protein. Oral administration of 50&#x000a0;mg/kg T1-11 or JMF-1907 for 3&#x000a0;months prevented neuronal cell death in the pontine nuclei by reversing the induced expression of BAX protein and decreased expression of B-cell lymphoma-extra large (BCL-xL) protein. Additionally, proteasome activity was significantly enhanced in the cerebellum and pontine nuclei in the treatment group, as indicated by increased levels of 7-amino-4-methylcoumarin (AMC). An improvement in motor functions was also observed in the treatment group compared to untreated animals, as indicated by the rotarod test [<xref ref-type="bibr" rid="CR57">57</xref>].</p><p id="Par60">A schematic of the possible activation of the UPS signalling pathway by natural remedies is shown in Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>. Natural remedies have been shown to activate UPS, resulting in the suppression of polyQ aggregation and motor dysfunction associated with SCA [<xref ref-type="bibr" rid="CR55">55</xref>&#x02013;<xref ref-type="bibr" rid="CR57">57</xref>]. The cAMP/PKA pathway is known to activate UPS and promote proteasome activity [<xref ref-type="bibr" rid="CR75">75</xref>] involving the activation of adenylate cyclase 6 through the A<sub>2A</sub> receptor [<xref ref-type="bibr" rid="CR76">76</xref>]. Chou et al. [<xref ref-type="bibr" rid="CR57">57</xref>] reported that the activation of A<sub>2A</sub> receptor by T1-11 and JMF-1907 could enhance proteasome activity and promote degradation of ubiquitin proteins. Similar findings were later reported by Chen et al. [<xref ref-type="bibr" rid="CR55">55</xref>, <xref ref-type="bibr" rid="CR56">56</xref>] using puerarin and daidzein compounds extracted from <italic>R. glutinosa</italic> and <italic>P. lobata</italic>. Inhibition of A<sub>2A</sub> receptor using an A<sub>2A</sub> antagonist blocked the effects induced by T1-11 and JMF-1907. This suggests the stimulation of A<sub>2A</sub> receptor is required for UPS activation [<xref ref-type="bibr" rid="CR57">57</xref>]. The suppression of polyQ aggregation was reported to prevent polyQ-induced cell death via suppression of BCL-2-associated X (BAX), and caspase-3 and -9 activities, while enhancing B-cell lymphoma 2 (BCL) expression [<xref ref-type="bibr" rid="CR55">55</xref>&#x02013;<xref ref-type="bibr" rid="CR57">57</xref>].<fig id="Fig3"><label>Fig.&#x000a0;3</label><caption><p>Schematic diagram of the activation of UPS by natural remedies against polyQ-induced SCA. <italic>ATP</italic> adenosine triphosphate, c<italic>AMP</italic> cyclic adenosine monophosphate, PKA protein kinase, <italic>PolyQ</italic> polyglutamine, <italic>BAX</italic> BCL-2-associated X, <italic>BCL</italic> B-cell lymphoma</p></caption><graphic xlink:href="13020_2020_414_Fig3_HTML" id="MO3"/></fig></p></sec><sec id="Sec11"><title>Activation of antioxidant pathways</title><p id="Par61">Oxidative damage occurs when reactive oxygen species (ROS) generation exceeds the antioxidant capacity of intracellular antioxidant enzymes [<xref ref-type="bibr" rid="CR77">77</xref>]. It was shown that the accumulation of polyQ aggregates can cause the depletion of antioxidants including glutathione (GSH), superoxide dismutase (SOD) and catalase (CAT), contributing to the accumulation of ROS and oxidative damage [<xref ref-type="bibr" rid="CR78">78</xref>, <xref ref-type="bibr" rid="CR79">79</xref>]. Patients diagnosed with SCA3 were reported to have reduced levels of glutathione and other thiols, which increased their susceptibility to oxidative damage [<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR80">80</xref>]. This condition may contribute to ROS-induced DNA damage and cell death, leading to motor dysfunctions associated with the disorder [<xref ref-type="bibr" rid="CR59">59</xref>, <xref ref-type="bibr" rid="CR81">81</xref>, <xref ref-type="bibr" rid="CR82">82</xref>] Furthermore, the presence of ROS promoted protein aggregation, causing further generation of ROS [<xref ref-type="bibr" rid="CR59">59</xref>]. Therefore, restoration of endogenous antioxidant levels by natural remedies could serve as a therapeutic strategy against SCAs.</p><p id="Par62">Three derived compounds genipin, geniposide and crocin and the aqueous extract of <italic>Gardenia jasminoides</italic> were investigated for their antioxidant activities in in vitro models of SCA3 using HEK-293 and SH-SY5Y cells expressing mutant ataxin-3 proteins [<xref ref-type="bibr" rid="CR58">58</xref>]. The presence of polyQ aggregates in the cells were observed to suppress the expression of nuclear factor erythroid 2-related factor 2 (NRF2), an antioxidant marker. Pre-treatment with aqueous extract (1-10 g/mL), genipin (50&#x02013;500&#x000a0;nM), geniposide (500&#x000a0;nM) or crocin (100&#x000a0;nM) for 8&#x000a0;h showed no cytotoxicity in the cells, as indicated by MTT assay. Pre-treatment with the extract or compounds restored the depleted expression of NRF2 and downstream antioxidant enzymes NAD(P)H quinone dehydrogenase 1 (NQO1), glutamate-cysteine ligase catalytic subunit (GCLC), and glutathione S-transferase pi 1 (GSTP1), while suppressing ROS levels and polyQ aggregation, as detected by low ROS fluorescence and GFP intensities. Overexpression of NRF2 in cells suppressed polyQ aggregation, whereas knockdown of its gene promoted polyQ aggregation. These findings suggest the involvement of antioxidant genes in the anti-aggregation effects in cells. Pre-treatment with extract or compounds did not significantly change DPPH (2,2-diphenyl-1-picrylhydrazyl) scavenging activity, suggesting DPPH radical scavenging is not a major factor in the anti-aggregation effects [<xref ref-type="bibr" rid="CR58">58</xref>].</p><p id="Par63">Similar findings were reported by Chen et al. [<xref ref-type="bibr" rid="CR59">59</xref>] using the aqueous extract of <italic>Glycyrrhiza inflata</italic> and its compounds licochalcone A and ammonium glycyrrhizinate (AMGZ) in in vitro models of SCA3 using HEK-293 and SH-SY5Y cells expressing mutant ataxin-3 proteins. Pre-treatment with aqueous extract (50 &#x000b5;g/mL), licochalcone A (10&#x000a0;nM) or AMGZ (1 &#x000b5;M) for 8&#x000a0;h showed low cytotoxicity in cells, as indicated by MTT assay. However, the extract or compounds upregulated the expression of peroxisome proliferator-activated receptor &#x003b3; coactivator 1&#x003b1; (PGC-1&#x003b1;), a regulator of the mitochondrial antioxidant defence system, and its downstream targets, NRF2, NQO1, SOD2, cytochrome c (CYCS) and heme oxygenase 1 (HMOX1), as detected by Western blot analysis. Oxidative damage was reduced through promotion of the glutathione/oxidised glutathione (GSH/GSSG) ratio, suppression of ROS levels and polyQ aggregation [<xref ref-type="bibr" rid="CR59">59</xref>].</p><p id="Par64">Pohl et al. [<xref ref-type="bibr" rid="CR61">61</xref>] investigated the antioxidant activities of ethanol extract from rapeseed pomace, a by-product of <italic>Brassica napus</italic> using Soxhlet extraction. Administration of ethanol extract (1-5&#x000a0;mg/mL) in an in vivo model of SCA3 using transgenic <italic>Caenorhabditis elegans</italic> expressing mutant ataxin-3 protein showed no toxicity, as detected by food clearance assay. Ethanol extract treatment promoted the expression of glutathione S-transferase 4 (GST4) and SOD3, which are involved in GSH metabolism and mitochondrial manganese SOD synthesis, respectively. Furthermore, ethanol extract improved motor function in transgenic <italic>C. elegans</italic> comparable with the wild type, as observed by a motility assay. Knockdown of GST4 gene in <italic>C. elegans</italic> abolished the improvement in motor function by ethanol extract. Pohl et al. [<xref ref-type="bibr" rid="CR61">61</xref>] suggested that the positive effects of rapeseed pomace extract were dependent on GST4 expression. Moreover, sinapine, a major compound derived from the ethanol extract, also demonstrated improvement in motor function of transgenic <italic>C. elegans</italic>, but it was less effective than the whole extract. This indicates additional compounds in conjunction with sinapine contributed to the positive effects of ethanol extract [<xref ref-type="bibr" rid="CR61">61</xref>].</p><p id="Par65">Shaoyao Gancao Tang is a Chinese traditional herbal formulation consisting of <italic>Paeonia lactiflora</italic>&#x000a0;and&#x000a0;<italic>Glycyrrhiza uralensis</italic> in a 1:1 ratio. In a study by Chen et al. [<xref ref-type="bibr" rid="CR65">65</xref>], the antioxidant activities of the formulation were evaluated in in vitro models of SCA17 using HEK 293 and SH-SY5Y cells expressing mutant TATA-box binding protein (TBP), and in vivo transgenic mouse model of SCA17 overexpressing TBP. Pre-treatment with the formulation (0.001&#x02013;100&#x000a0;&#x000b5;g/mL) in cells for 8&#x000a0;h demonstrated no cytotoxicity, as indicated by MTT assay. The formulation was able to restore the expression of PGC-1&#x003b1; and NRF2, and their downstream targets, CYCS, GCLC and NQO1, as detected by Western blot analysis. Furthermore, suppression of polyQ aggregation was observed in cells, as shown by low GFP intensity. Administration of 0.4% Shaoyao Gancao Tang in the drinking water of the mouse model improved gait coordination and suppressed hyperactivity, as indicated by footprint and locomotor test, respectively [<xref ref-type="bibr" rid="CR65">65</xref>].</p><p id="Par66">Zhengan Xifeng Tang is a Chinese traditional herbal formulation consisting of various mixtures of medicinal plants. The positive effects of the formulation were investigated by Okabe et al. [<xref ref-type="bibr" rid="CR63">63</xref>] in a 60-year-old female patient diagnosed with typical SCA6. Oral administration of the formulation for 2 months showed visible alleviation of ataxia symptoms including vertigo and titubation. Motor function was also observed to be improved, as indicated by the International Cooperative Ataxia Rating Scale (ICARS). At 1&#x000a0;year after treatment discontinuation, the patient experienced a relapse in ataxia symptoms, although re-administration of the formulation alleviated the deteriorating symptoms. However, the patient relapsed a second time after another 15&#x000a0;months after treatment discontinuation, which was again alleviated by the treatment [<xref ref-type="bibr" rid="CR63">63</xref>]. Similar findings were demonstrated in another study by Okabe [<xref ref-type="bibr" rid="CR64">64</xref>] in 71-year-old female patient diagnosed with typical SCA6. Although the mechanisms of Zhengan Xifeng Tang on SCA6 were not identified from these studies, it was suggested that the positive effects may be attributed to the antioxidant and anticonvulsant activity of the herb formulation [<xref ref-type="bibr" rid="CR63">63</xref>, <xref ref-type="bibr" rid="CR64">64</xref>].</p><p id="Par67">The activation of the antioxidant pathway by natural remedies is shown in Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>. The antioxidant activities of natural remedies were shown to have therapeutic effects against cell damage in SCA through the activation of NRF2/ARE&#x000a0;(antioxidant response element). This antioxidant pathway involved the upregulation of various phase II detoxifying/antioxidant enzymes that attenuated the oxidative damage and prevented ROS-induced cell death [<xref ref-type="bibr" rid="CR83">83</xref>]. In a study by Chen et al. [<xref ref-type="bibr" rid="CR65">65</xref>], Shaoyao Gancao Tang upregulated the expression of NRF2 and PGC-1&#x003b1;, a coactivator of NRF2, which suppressed ROS levels in vitro and restored motor function in transgenic SCA17 mice. Studies by Chang et al. [<xref ref-type="bibr" rid="CR58">58</xref>] and Chen et al. [<xref ref-type="bibr" rid="CR59">59</xref>] showed that <italic>G. jasminoides</italic> and <italic>G. inflata</italic> could activate downstream targets of NRF2 and PGC-1&#x003b1; (e.g., SOD2, CYCS, NAD(P)H, NQO1, GCLC and GSTP1), which effectively suppressed ROS levels and polyQ aggregation. In contrast, knockdown of PGC-1&#x003b1; and/or NRF2 promoted aggregation and attenuated the anti-aggregation activity of Shaoyao Gancao Tang, <italic>G. jasminoides</italic> and <italic>G. inflata</italic>, which suggest PGC-1&#x003b1; and NRF2 are involved in the positive effects on SCA [<xref ref-type="bibr" rid="CR58">58</xref>, <xref ref-type="bibr" rid="CR59">59</xref>, <xref ref-type="bibr" rid="CR65">65</xref>].<fig id="Fig4"><label>Fig.&#x000a0;4</label><caption><p>Schematic diagram of the activation of the antioxidant signalling pathway by natural remedies against polyQ-induced SCA. <italic>PGC-1&#x003b1;</italic> peroxisome proliferator-activated receptor &#x003b3;, <italic>NRF2</italic> nuclear factor erythroid 2-related factor 2, <italic>ARE</italic> antioxidant response element, <italic>CYCS</italic> cytochrome c, <italic>NQO1</italic> NAD(P)H Quinone Dehydrogenase 1, <italic>GCLC</italic> glutamate-cysteine ligase catalytic subunit, <italic>GSTP1</italic> glutathione S-transferase pi 1, <italic>SOD2</italic> superoxide dismutase 2, <italic>PolyQ</italic> polyglutamine, <italic>ROS</italic> reactive oxygen species</p></caption><graphic xlink:href="13020_2020_414_Fig4_HTML" id="MO4"/></fig></p><p id="Par68">Friedreich&#x02019;s ataxia (FRDA) is an autosomal recessive disorder caused by the abnormal expansion of GAA repeats contributing to suppressed expression of frataxin (FXN) protein [<xref ref-type="bibr" rid="CR84">84</xref>]. Evidence shows that frataxin deficiency in FRDA impairs the intracellular antioxidant defence system, resulting in decreased GSH levels [<xref ref-type="bibr" rid="CR85">85</xref>&#x02013;<xref ref-type="bibr" rid="CR87">87</xref>] and expressions of antioxidant enzymes including SOD, CAT, glutaredoxin, and thioredoxin [<xref ref-type="bibr" rid="CR88">88</xref>]. Additionally, excessive ROS is generated by an iron-dependent Fenton reaction and mitochondrial dysfunction. The compromised antioxidant defence system and ROS accumulation contribute to the unregulated increase in oxidative damage, leading to DNA damage and cell death [<xref ref-type="bibr" rid="CR89">89</xref>&#x02013;<xref ref-type="bibr" rid="CR92">92</xref>].</p><p id="Par69">Lew et al. [<xref ref-type="bibr" rid="CR66">66</xref>] investigated the antioxidant activities of a standardised aqueous extract of <italic>Hericium erinaceus</italic> in an in vitro model of FRDA involving L-Buthionine sulfoximine (L-BSO)-induced human dermal fibroblast expressing abnormal expansion of GAA triplet repeat. L-Buthionine sulfoximine is an inhibitor of &#x003b3;-glutamylcysteine synthetase, which plays a role in GSH biogenesis. Cells treated with L-BSO had reduced levels of GSH, which increased the susceptibility of cells to oxidative damage [<xref ref-type="bibr" rid="CR93">93</xref>]. Treatment of cells with the extract (32&#x000a0;mg/mL) for 24&#x000a0;h restored the GSH depletion, as shown by an increased GSH/GSSG ratio. The extract also reduced the lactate dehydrogenase (LDH) level and apoptotic body formation, as detected by LDH assay and Hoechst 33258 staining, respectively. The findings suggest the extract was able to prevent oxidative damage-induced cell death by preventing GSH depletion [<xref ref-type="bibr" rid="CR66">66</xref>].</p></sec><sec id="Sec12"><title>Maintenance of intracellular calcium homeostasis</title><p id="Par70">Calcium ions are important signalling molecules that control a wide variety of cellular processes including muscle control, cell signalling and cell growth [<xref ref-type="bibr" rid="CR94">94</xref>]. Accumulating evidence shows that polyQ aggregates impair calcium homeostasis and induce abnormal calcium ion influx in Purkinje cells through ionotropic &#x003b1;-amino-3-hydroxyl-5-methyl-4-isoxazole-propionate (AMPA) receptors and metabotropic glutamate receptors (mGluR) [<xref ref-type="bibr" rid="CR95">95</xref>&#x02013;<xref ref-type="bibr" rid="CR98">98</xref>]. The accumulation of calcium ions leads to the formation of microaggregates, eventually forming larger inclusion bodies, leading to neuronal degeneration and cell death, and compromised cerebellar output and motor function [<xref ref-type="bibr" rid="CR67">67</xref>]. Natural remedies that can restore calcium homeostasis could potentially treat polyQ disorders.</p><p id="Par71">A study by Huang et al. [<xref ref-type="bibr" rid="CR62">62</xref>] investigated the positive effects of EGb 761, a standardised extract of <italic>Ginkgo biloba</italic>, in in vitro models of SCA17 using HEK 293 and SH-SY5Y cells expressing mutant TATA-box binding protein (TBP), and an in vivo transgenic mouse model overexpressing TBP. Pre-treatment with EGb 761 (20&#x000a0;&#x003bc;g/mL) for 1&#x000a0;h restored cellular calcium homeostasis and suppressed calcium influx, as indicated by reduced calcium green fluorescence intensity. Additionally, there was a reduction in calcium-dependent pro-apoptotic marker expressions, including calpain 2, BAX, caspase 3 and poly (adenosine diphosphate-ribose) polymerase (PARP), as detected by Western blot analysis. Intraperitoneal injection of EGb 761 (100&#x000a0;mg/kg) in transgenic mice demonstrated improved motor function by rotarod test. Moreover, EGb 761 prevented the disruption of calbindin integrity, as indicated by immunohistochemistry analysis [<xref ref-type="bibr" rid="CR62">62</xref>]. Calbindins are major proteins expressed on neurons such as Purkinje cells, which play a role in motor function, calcium homeostasis and cell survival [<xref ref-type="bibr" rid="CR99">99</xref>, <xref ref-type="bibr" rid="CR100">100</xref>]. Similar findings were also reported by Chen et al. [<xref ref-type="bibr" rid="CR65">65</xref>] using Shaoyao Gancao Tang in Purkinje cells of SCA17 mice detected by calbindin staining. A schematic of the maintenance of intracellular calcium homeostasis by natural remedies is shown in Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref>.<fig id="Fig5"><label>Fig.&#x000a0;5</label><caption><p>Schematic diagram of the maintenance of intracellular calcium homeostasis by natural remedies against polyQ-induced SCA. <italic>BAX</italic> BCL-2 associated X, <italic>PARP</italic> poly (adenosine diphosphate-ribose) polymerase</p></caption><graphic xlink:href="13020_2020_414_Fig5_HTML" id="MO5"/></fig></p></sec><sec id="Sec13"><title>Regulation of chaperones</title><p id="Par72">Heat shock proteins (HSPs) are evolutionarily conserved chaperones ubiquitous in organisms and are responsible for cell survival by facilitating protein assembly, folding, translocation, stabilisation and degradation [<xref ref-type="bibr" rid="CR101">101</xref>, <xref ref-type="bibr" rid="CR102">102</xref>]. Previous studies by Chen et al. [<xref ref-type="bibr" rid="CR103">103</xref>] and Lee et al. [<xref ref-type="bibr" rid="CR104">104</xref>] demonstrated the presence of TBP induced the sequestration of nuclear transcription factor Y (NFY) complexes and suppressed its downstream targets including the heat shock 70&#x000a0;kDa protein (HSPA) 5 and 8. Studies also showed that upregulation of HSPs could suppress polyQ aggregation and protect against polyQ-induced toxicity [<xref ref-type="bibr" rid="CR105">105</xref>&#x02013;<xref ref-type="bibr" rid="CR109">109</xref>]. Natural remedies that can restore HSP expression and function could serve as an alternative therapeutic option for polyQ-induced SCAs.</p><p id="Par73">Chang et al. [<xref ref-type="bibr" rid="CR60">60</xref>] investigated the effects of <italic>Paeonia lactiflora</italic> and its major compound paeoniflorin on HSPs in in vitro models of SCA3 using HEK-293 and SH-SY5Y cells expressing mutant ataxin-3 proteins. Pre-treatment with <italic>P. lactiflora</italic> (2-50&#x02009;<italic>&#x003bc;</italic>g/mL) for 24&#x000a0;h showed no cytotoxicity, as assessed by MTT assay. The extract and compound upregulated the expression of heat shock transcription factor 1 (HSF1) and heat shock protein 70 (HSP70) chaperone in cells. Additionally, suppression of polyQ aggregation was observed in the cells, as shown by low GFP intensity. Overexpression of HSP1 also resulted in suppressed polyQ aggregation, suggesting that the positive effects of the extract and compound were modulated by HSPs. The role of HSPs in suppressing polyQ aggregation was further supported by Chen et al. [<xref ref-type="bibr" rid="CR65">65</xref>] in an in vivo model of SCA17. Administration of Shaoyao Gancao Tang promoted HSPA5 expression and suppressed TBP protein aggregation in transgenic mice leading to improved motor function in the rotarod test [<xref ref-type="bibr" rid="CR65">65</xref>]. The regulation of chaperones by natural remedies is shown in Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6</xref>.<fig id="Fig6"><label>Fig.&#x000a0;6</label><caption><p>Schematic diagram of the regulation of chaperones by natural remedies against polyQ-induced SCA. <italic>HSF1</italic> heat shock transcription factor 1, <italic>HSPA5</italic> heat shock 70 kDa protein 5, <italic>HSP70</italic> heat shock protein 70</p></caption><graphic xlink:href="13020_2020_414_Fig6_HTML" id="MO6"/></fig></p></sec></sec></sec><sec id="Sec14"><title>Limitations and future prospects</title><p id="Par74">There are valid concerns on the use of natural remedies in HA drug discovery and development. Natural remedies are often initially experimented as crude extracts and due to the high abundance of non-desirable components, bioassay-guided isolation of target compounds must be performed with subsequent identification [<xref ref-type="bibr" rid="CR110">110</xref>, <xref ref-type="bibr" rid="CR111">111</xref>]. Furthermore, metal impurities, fluorescence-interfering, the presence of non-polar or polar compounds in the extracts may provide inaccurate results for some bioassays. Therefore, such compounds must first be removed depending on the assay system to avoid interference [<xref ref-type="bibr" rid="CR112">112</xref>]. The process requires more time and effort as compared to high-throughput screening of chemical compound libraries [<xref ref-type="bibr" rid="CR110">110</xref>, <xref ref-type="bibr" rid="CR111">111</xref>].</p><p id="Par75">Another impediment in its acceptance is the lack of standard profile for quality control, cost per sample, complexity of resupply and variation of chemical composition. Natural remedies harvested from the wild are susceptible to environmental factors such as deforestation, pollution, global warming and anthropic pressure which hinders their habitat and limits availability. In addition, discrepancy in growth requirements such as soil composition, weather, altitude and storage conditions contribute to variation of chemical composition. The composition may also be affected during processing and isolation as some compounds may undergo transformation and degradation [<xref ref-type="bibr" rid="CR110">110</xref>&#x02013;<xref ref-type="bibr" rid="CR112">112</xref>]. The ecological issues can be resolved through the generation of a controlled cultivation system which provides optimal yield and uniform composition, preventing batch to batch variation [<xref ref-type="bibr" rid="CR113">113</xref>]. Nevertheless, majority of the natural remedies worldwide are still harvested from the wild [<xref ref-type="bibr" rid="CR112">112</xref>]. This is due to the high commercial risk associated with generating the system as the market is unpredictable and the duration required for the establishment is long [<xref ref-type="bibr" rid="CR113">113</xref>].</p><p id="Par76">It is worthy to emphasise that HA is a rare genetic disorder with severe survival outcomes; hence, development of translational models of human-specific HA is rather limited. Studies of innovative treatment with small sample size by individual laboratories should by no means be substituted by multi-centre pre-clinical mouse studies. Nevertheless, the limitations of such smaller studies should be clearly defined by differentiating between proof-of-concept studies and pre-clinical testing studies.</p><p id="Par77">Although various forms of HA have been identified, only four subtypes of HA (SCA3, 6, 17 and FRDA) were investigated with natural remedies in the reviewed studies. Furthermore, the studies demonstrating the positive effects of natural remedies on HA were largely conducted with pre-clinical models such as in vitro cell culture models and in vivo animal models. While these models have facilitated the understanding of mechanisms and signalling pathways in the treatment of HA, the results need to be validated in human studies. Additionally, although there are no models that can reproduce all symptoms of HA patients or cellular mechanisms involved, mammals (<italic>Drosophila</italic>, transgenic and knockout mice) and mammalian cell lines (patient-derived cells, iPSCs and iPSC-derived cells) are currently the most useful models, owing to their close physiological features to HA diseases [<xref ref-type="bibr" rid="CR114">114</xref>, <xref ref-type="bibr" rid="CR115">115</xref>]. Due to the complexity and heterogeneity of HA pathogenesis, current approaches are focusing on the development of therapeutic strategies that target different stages of the cellular pathogenesis, thus making comparison across the studies challenging [<xref ref-type="bibr" rid="CR115">115</xref>]. Moreover, it is difficult to compare transgenic mice derived from different mouse strains as the manifestation of the targeted mutations may be interfered by their phenotypic traits of the original strain [<xref ref-type="bibr" rid="CR116">116</xref>].</p><p id="Par78">In spite of the fact that natural remedies are shown to produce significant improvement in HA patients, the results of such studies are limited by the sample size and possible bias to ethnicity and gender. Clinical studies by Okabe et al. [<xref ref-type="bibr" rid="CR63">63</xref>] and Okabe [<xref ref-type="bibr" rid="CR64">64</xref>] were each conducted with only one test subject. Furthermore, both test subjects were elderly Japanese female aged 60 and 71. The limited number of test subject and lack of diversity in terms of age and ethnicity may affect the reliability of the findings [<xref ref-type="bibr" rid="CR117">117</xref>]. Another major limitation is the lack of safety and efficacy profile for the natural remedies and compounds studied in this review. It is not known whether the dosage of decoctions with complex formulations and compounds administered may lead to potential toxicity, adverse effects or will be present at the intended site of action in sufficient concentration [<xref ref-type="bibr" rid="CR118">118</xref>&#x02013;<xref ref-type="bibr" rid="CR120">120</xref>]. This is also further complicated with the lack of understanding of the molecular targets and mechanism involving the natural remedies [<xref ref-type="bibr" rid="CR120">120</xref>]. Greater understanding of the pharmacokinetic and pharmacodynamics profiles of these compounds will support more effective clinical trials in the future.</p><p id="Par79">A more systematic approach in cataloguing the potential effects of natural remedies/compounds will speed up the drug discovery process, in order to have more investigations done on unexplored compounds. Detailed mode of actions for each compound can be delineated using high throughput methods such as NGS coupled with various other confirmative studies such as transcriptomic validation, protein translation and function as well as epigenetic studies. Integrative analysis of such &#x02018;omics&#x02019; data will allow researchers with an unprecedented speed in understanding the underlying pathophysiology this rare disease, developing effective biomarkers and pursuing meaningful clinical testing [<xref ref-type="bibr" rid="CR121">121</xref>]. Studies on specific HA can be undertaken using relevant genetic resources or repositories of biologic samples. NGS can be implemented on HA research in identifying and validating potential targets through epigenetic studies, differential gene expression, genome sequencing and protein translation rates. Moreover, NGS sequencing can be used to discover biomarkers that can reflect the mechanism of action regulated by the natural remedy or compound [<xref ref-type="bibr" rid="CR122">122</xref>]. These pre-clinical studies can provide proof of concept and mechanism in establishing the pharmacodynamic parameters of these remedies and compounds prior to clinical testing.</p><p id="Par80">As pre-clinical and clinical studies are currently lacking, effort should be directed towards testing using polyQ animal models and randomised controlled trials, respectively, including for forms of HA not yet studied. Improved studies should be done where study conclusions are uncertain due to methodological insufficiencies or discrepancies. Comparative studies should be done with current treatments versus natural remedies (single compound or the mixture) to ascertain the potential of the latter as supplements or alternative treatments for HA. Additionally, further studies can be conducted towards investigating whether the natural remedies could modulate HA through other pathways not discussed in this review.</p><p id="Par81">In addition, a successful planning and execution of a&#x000a0;research consortium involving Friedreich&#x02019;s Ataxia Research Alliance (FARA) and National Ataxia Foundation (NAF) opens new possibilities for HA research. Such effort will foster cross-nationals translational research in the development of alternative treatments for HA. Multidisciplinary team involvement and input form the allied health professionals are also critical in the management of HA, particularly in the palliative stage. Indeed, all these efforts will require strong commitment not only from the researchers, but also the patients diagnosed with HA as well as their family members.</p></sec><sec id="Sec15"><title>Conclusion</title><p id="Par82">In conclusion, the systematic review provides an overview of the available evidence from pre-clinical and clinical trials pertaining to the natural remedies in improving or halting the progression of HA. Nevertheless, there&#x000a0;has been&#x000a0;an increasing&#x000a0;concern&#x000a0;by the clinicians about the&#x000a0;potential&#x000a0;of interactions of natural remedies with prescribed drugs. The mechanisms underlying&#x000a0;natural remedies-drug interactions&#x000a0;are always&#x000a0;difficult to predict. Another issue is the general lack&#x000a0;of understanding on the composition and pharmacological actions of natural remedies. Therefore, research evidence is necessary to ensure its&#x000a0;safety and effectiveness and to warrant the integration of natural remedies into evidence-based clinical practice.</p></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>HA</term><def><p id="Par6">Hereditary ataxia</p></def></def-item><def-item><term>SCA</term><def><p id="Par7">Spinocerebellar ataxia</p></def></def-item><def-item><term>CAG</term><def><p id="Par8">Cytosine-Adenine-Guanine</p></def></def-item><def-item><term>EA</term><def><p id="Par9">Episodic ataxia</p></def></def-item><def-item><term>FRDA</term><def><p id="Par10">Friedreich&#x02019;s ataxia</p></def></def-item><def-item><term>AT</term><def><p id="Par11">Ataxia-telangiectasia</p></def></def-item><def-item><term>AOA</term><def><p id="Par12">Ataxia oculomotor apraxia</p></def></def-item><def-item><term>FXTAS</term><def><p id="Par13">Fragile X tremor-ataxia syndrome</p></def></def-item><def-item><term>TCM</term><def><p id="Par14">Traditional Chinese medicine</p></def></def-item><def-item><term>PRISMA</term><def><p id="Par15">Preferred Reporting Items for Systematic Review and Meta-Analyses</p></def></def-item><def-item><term>HEK-293</term><def><p id="Par16">Human embryonic kidney 293 cells</p></def></def-item><def-item><term>PolyQ</term><def><p id="Par17">Polyglutamine</p></def></def-item><def-item><term>UPS</term><def><p id="Par18">Ubiquitin-proteasome system</p></def></def-item><def-item><term>cAMP</term><def><p id="Par19">Cyclic adenosine monophosphate</p></def></def-item><def-item><term>PKA</term><def><p id="Par20">Protein kinase</p></def></def-item><def-item><term>ROS</term><def><p id="Par21">Reactive oxygen species</p></def></def-item><def-item><term>NRF2</term><def><p id="Par22">Nuclear factor erythroid 2&#x02013;related factor 2</p></def></def-item><def-item><term>AMGZ</term><def><p id="Par23">Ammonium glycyrrhizinate</p></def></def-item><def-item><term>MTT</term><def><p id="Par24">3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide</p></def></def-item><def-item><term>GFP</term><def><p id="Par25">Green fluorescent protein</p></def></def-item><def-item><term>LDH</term><def><p id="Par26">Lactate dehydrogenase</p></def></def-item><def-item><term>BAX</term><def><p id="Par27">BCL-2-associated X protein</p></def></def-item><def-item><term>BCL2</term><def><p id="Par28">B cell lymphoma 2</p></def></def-item><def-item><term>T1-11</term><def><p id="Par29">N<sup>6</sup>-(4-Hydroxybenzyl) adenosine</p></def></def-item><def-item><term>JMF1907</term><def><p id="Par30">N<sup>6</sup>-(3-Indolylethyl) adenosine</p></def></def-item><def-item><term>GSH</term><def><p id="Par31">Glutathione</p></def></def-item><def-item><term>SOD</term><def><p id="Par32">Superoxide dismutase</p></def></def-item><def-item><term>CAT</term><def><p id="Par33">Catalase</p></def></def-item><def-item><term>NQO1</term><def><p id="Par34">NAD(P)H quinone dehydrogenase 1</p></def></def-item><def-item><term>GCLC</term><def><p id="Par35">Glutamate-cysteine ligase catalytic subunit</p></def></def-item><def-item><term>GSTP1</term><def><p id="Par36">Glutathione S-transferase pi 1</p></def></def-item><def-item><term>CYCS</term><def><p id="Par37">Cytochrome c</p></def></def-item><def-item><term>GSSG</term><def><p id="Par38">Oxidised glutathione</p></def></def-item><def-item><term>GST4</term><def><p id="Par39">Glutathione S-transferase 4</p></def></def-item><def-item><term>TBP</term><def><p id="Par40">TATA-box binding protein</p></def></def-item><def-item><term>PGC-1&#x003b1;</term><def><p id="Par41">Peroxisome proliferator-activated receptor &#x003b3; coactivator 1&#x003b1;</p></def></def-item><def-item><term>HSP</term><def><p id="Par42">Heat shock protein</p></def></def-item></def-list></glossary><fn-group><fn><p><bold>Publisher's Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><ack><title>Acknowledgements</title><p>This work was funded by University of Malaya Faculty of Medicine Research Grant GPF003C-2019. We would like to thank Public Service Department Malaysia for the scholarship support for the postgraduate study and&#x000a0;Dr Mohamad Hariz Hamka bin Mahamad of the Faculty&#x000a0;of Medicine, University of Malaya for providing&#x000a0;hand-drawn images of natural remedies.</p></ack><notes notes-type="author-contribution"><title>Authors&#x02019; contributions</title><p>Conceptualisation KHW, Original draft preparation MWLP and SYL. Review and editing KHW, LWL, IC and WKSL. Visualisation&#x000a0;MWLP and SYL, Supervision KHW, LWL and IC. All authors read and approved the final manuscript.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>University of Malaya Faculty of Medicine Research Grant GPF003C-2019.</p></notes><notes notes-type="data-availability"><title>Availability of data and materials</title><p>Not applicable.</p></notes><notes id="FPar1"><title>Ethics approval and consent to participate</title><p id="Par83">Not applicable.</p></notes><notes id="FPar2"><title>Consent for publication</title><p id="Par84">Not applicable.</p></notes><notes id="FPar3" notes-type="COI-statement"><title>Competing interests</title><p id="Par85">The authors declare that they have no competing interests.</p></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Akbar</surname><given-names>U</given-names></name><name><surname>Ashizawa</surname><given-names>T</given-names></name></person-group><article-title>Ataxia</article-title><source>Neurol Clin</source><year>2015</year><volume>33</volume><issue>1</issue><fpage>225</fpage><lpage>248</lpage><pub-id pub-id-type="doi">10.1016/j.ncl.2014.09.004</pub-id><?supplied-pmid 25432731?><pub-id pub-id-type="pmid">25432731</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Albernaz</surname><given-names>PLM</given-names></name><name><surname>Zuma e Maia</surname><given-names>FZ</given-names></name><name><surname>Carmona</surname><given-names>S</given-names></name><name><surname>Cal</surname><given-names>RVR</given-names></name><name><surname>Zalazar</surname><given-names>G</given-names></name></person-group><article-title>Ataxia</article-title><source>The new neurotology: a comprehensive clinical guide</source><year>2019</year><publisher-loc>Cham</publisher-loc><publisher-name>Springer</publisher-name><fpage>181</fpage><lpage>91</lpage></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Teive</surname><given-names>HAG</given-names></name><name><surname>Ashizawa</surname><given-names>T</given-names></name></person-group><article-title>Primary and secondary ataxias</article-title><source>Curr Opin Neurol</source><year>2015</year><volume>28</volume><issue>4</issue><fpage>413</fpage><lpage>422</lpage><pub-id pub-id-type="doi">10.1097/WCO.0000000000000227</pub-id><?supplied-pmid 26132530?><pub-id pub-id-type="pmid">26132530</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sarva</surname><given-names>H</given-names></name><name><surname>Shanker</surname><given-names>VL</given-names></name></person-group><article-title>Treatment options in degenerative cerebellar ataxia: a systematic review</article-title><source>Mov Disord Clin Pract</source><year>2014</year><volume>1</volume><issue>4</issue><fpage>291</fpage><lpage>298</lpage><pub-id pub-id-type="doi">10.1002/mdc3.12057</pub-id><?supplied-pmid 30363941?><pub-id pub-id-type="pmid">30363941</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beaudin</surname><given-names>M</given-names></name><name><surname>Matilla-Due&#x000f1;as</surname><given-names>A</given-names></name><name><surname>Soong</surname><given-names>B-W</given-names></name><name><surname>Pedroso</surname><given-names>JL</given-names></name><name><surname>Barsottini</surname><given-names>OG</given-names></name><name><surname>Mitoma</surname><given-names>H</given-names></name><name><surname>Tsuji</surname><given-names>S</given-names></name><name><surname>Schmahmann</surname><given-names>JD</given-names></name><name><surname>Manto</surname><given-names>M</given-names></name><name><surname>Rouleau</surname><given-names>GA</given-names></name><name><surname>Klein</surname><given-names>C</given-names></name><name><surname>Dupre</surname><given-names>N</given-names></name></person-group><article-title>The classification of autosomal recessive cerebellar ataxias: a consensus statement from the society for research on the cerebellum and ataxias task force</article-title><source>Cerebellum</source><year>2019</year><volume>18</volume><issue>6</issue><fpage>1098</fpage><lpage>1125</lpage><pub-id pub-id-type="doi">10.1007/s12311-019-01052-2</pub-id><?supplied-pmid 31267374?><pub-id pub-id-type="pmid">31267374</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buijsen</surname><given-names>RAM</given-names></name><name><surname>Toonen</surname><given-names>LJA</given-names></name><name><surname>Gardiner</surname><given-names>SL</given-names></name><name><surname>van Roon-Mom</surname><given-names>WMC</given-names></name></person-group><article-title>Genetics, mechanisms, and therapeutic progress in polyglutamine spinocerebellar ataxias</article-title><source>Neurotherapeutics</source><year>2019</year><volume>16</volume><issue>2</issue><fpage>263</fpage><lpage>286</lpage><pub-id pub-id-type="doi">10.1007/s13311-018-00696-y</pub-id><?supplied-pmid 30607747?><pub-id pub-id-type="pmid">30607747</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Bird</surname><given-names>TD</given-names></name></person-group><person-group person-group-type="editor"><name><surname>Adam</surname><given-names>MP</given-names></name><name><surname>Ardinger</surname><given-names>HH</given-names></name><name><surname>Pagon</surname><given-names>RA</given-names></name><name><surname>Wallace</surname><given-names>SE</given-names></name></person-group><article-title>Hereditary ataxia overview</article-title><source>GeneReviews<sup>&#x000ae;</sup> [Internet]</source><year>2019</year><publisher-loc>Seattle</publisher-loc><publisher-name>University of Washington</publisher-name></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>&#x000d6;z</surname><given-names>G</given-names></name><name><surname>Iltis</surname><given-names>I</given-names></name><name><surname>Hutter</surname><given-names>D</given-names></name><name><surname>Thomas</surname><given-names>W</given-names></name><name><surname>Bushara</surname><given-names>KO</given-names></name><name><surname>Gomez</surname><given-names>CM</given-names></name></person-group><article-title>Distinct neurochemical profiles of spinocerebellar ataxias 1, 2, 6, and cerebellar multiple system atrophy</article-title><source>Cerebellum</source><year>2011</year><volume>10</volume><issue>2</issue><fpage>208</fpage><lpage>217</lpage><pub-id pub-id-type="doi">10.1007/s12311-010-0213-6</pub-id><?supplied-pmid 20838948?><pub-id pub-id-type="pmid">20838948</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seidel</surname><given-names>K</given-names></name><name><surname>Siswanto</surname><given-names>S</given-names></name><name><surname>Brunt</surname><given-names>ERP</given-names></name><name><surname>den Dunnen</surname><given-names>W</given-names></name><name><surname>Korf</surname><given-names>H-W</given-names></name><name><surname>R&#x000fc;b</surname><given-names>U</given-names></name></person-group><article-title>Brain pathology of spinocerebellar ataxias</article-title><source>Acta Neuropathol</source><year>2012</year><volume>124</volume><issue>1</issue><fpage>1</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1007/s00401-012-1000-x</pub-id><pub-id pub-id-type="pmid">22684686</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>R&#x000fc;b</surname><given-names>U</given-names></name><name><surname>Sch&#x000f6;ls</surname><given-names>L</given-names></name><name><surname>Paulson</surname><given-names>H</given-names></name><name><surname>Auburger</surname><given-names>G</given-names></name><name><surname>Kermer</surname><given-names>P</given-names></name><name><surname>Jen</surname><given-names>JC</given-names></name><name><surname>Seidel</surname><given-names>K</given-names></name><name><surname>Korf</surname><given-names>H-W</given-names></name><name><surname>Deller</surname><given-names>T</given-names></name></person-group><article-title>Clinical features, neurogenetics and neuropathology of the polyglutamine spinocerebellar ataxias type 1, 2, 3, 6 and 7</article-title><source>Prog Neurobiol</source><year>2013</year><volume>104</volume><fpage>38</fpage><lpage>66</lpage><pub-id pub-id-type="doi">10.1016/j.pneurobio.2013.01.001</pub-id><?supplied-pmid 23438480?><pub-id pub-id-type="pmid">23438480</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Piccinin</surname><given-names>CC</given-names></name><name><surname>D&#x02019;Abreu</surname><given-names>A</given-names></name></person-group><person-group person-group-type="editor"><name><surname>Habas</surname><given-names>C</given-names></name></person-group><article-title>Neuroimaging in ataxias</article-title><source>The neuroimaging of brain diseases: structural and functional advances</source><year>2018</year><publisher-loc>Cham</publisher-loc><publisher-name>Springer</publisher-name><fpage>215</fpage><lpage>32</lpage></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meira</surname><given-names>AT</given-names></name><name><surname>Arruda</surname><given-names>WO</given-names></name><name><surname>Ono</surname><given-names>SE</given-names></name><name><surname>de Carvalho</surname><given-names>Neto A</given-names></name><name><surname>Raskin</surname><given-names>S</given-names></name><name><surname>Camargo</surname><given-names>CHF</given-names></name><name><surname>Teive</surname><given-names>HAG</given-names></name></person-group><article-title>Neuroradiological findings in the spinocerebellar ataxias</article-title><source>Tremor Other Hyperkinet Mov (N Y).</source><year>2019</year><pub-id pub-id-type="doi">10.7916/tohm.v0.682</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Vel&#x000e1;zquez-P&#x000e9;rez</surname><given-names>L</given-names></name><name><surname>Rodr&#x000ed;guez-Labrada</surname><given-names>R</given-names></name><name><surname>Freund</surname><given-names>H-J</given-names></name><name><surname>Auburger</surname><given-names>G</given-names></name></person-group><person-group person-group-type="editor"><name><surname>Gazulla</surname><given-names>J</given-names></name></person-group><article-title>Spinocerebellar ataxia type 2</article-title><source>Spinocerebellar ataxia</source><year>2012</year><publisher-loc>Rijeka</publisher-loc><publisher-name>InTech</publisher-name><fpage>77</fpage><lpage>102</lpage></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vel&#x000e1;zquez-P&#x000e9;rez</surname><given-names>LC</given-names></name><name><surname>Rodr&#x000ed;guez-Labrada</surname><given-names>R</given-names></name><name><surname>Fernandez-Ruiz</surname><given-names>J</given-names></name></person-group><article-title>Spinocerebellar ataxia type 2: clinicogenetic aspects, mechanistic insights, and management approaches</article-title><source>Front Neurol</source><year>2017</year><volume>8</volume><fpage>472</fpage><pub-id pub-id-type="doi">10.3389/fneur.2017.00472</pub-id><?supplied-pmid 28955296?><pub-id pub-id-type="pmid">28955296</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vale</surname><given-names>J</given-names></name><name><surname>Bugalho</surname><given-names>P</given-names></name><name><surname>Silveira</surname><given-names>I</given-names></name><name><surname>Sequeiros</surname><given-names>J</given-names></name><name><surname>Guimar&#x000e3;es</surname><given-names>J</given-names></name><name><surname>Coutinho</surname><given-names>P</given-names></name></person-group><article-title>Autosomal dominant cerebellar ataxia: frequency analysis and clinical characterization of 45 families from Portugal</article-title><source>Eur J Neurol</source><year>2010</year><volume>17</volume><issue>1</issue><fpage>124</fpage><lpage>128</lpage><pub-id pub-id-type="doi">10.1111/j.1468-1331.2009.02757.x</pub-id><?supplied-pmid 19659750?><pub-id pub-id-type="pmid">19659750</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><mixed-citation publication-type="other">de Assis AM, Saute JAM, Longoni A, Haas CB, Torrez VR, Brochier AW, Souza GN, Furtado GV, Gheno TC, Russo A, Monte TL, Castilhos RM, Schumacher-Schuh A, D&#x02019; Avila R, Donis KC, de Mello Rieder CR, Souza DO, Camey S, Leotti VB, Jardim LB, Portela LV. Peripheral oxidative stress biomarkers in spinocerebellar ataxia type 3/Machado&#x02013;Joseph disease. Front Neurol. 2017;8:485.&#x000a0;10.3389/fneur.2017.00485.</mixed-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>Z</given-names></name><name><surname>Shi</surname><given-names>C</given-names></name><name><surname>Zhou</surname><given-names>L</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Yang</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Mao</surname><given-names>C</given-names></name><name><surname>Luo</surname><given-names>H</given-names></name><name><surname>Xu</surname><given-names>G</given-names></name><name><surname>Xu</surname><given-names>Y</given-names></name></person-group><article-title>Metabolic profiling reveals biochemical pathways and potential biomarkers of spinocerebellar ataxia 3</article-title><source>Front Mol Neurosci</source><year>2019</year><volume>12</volume><fpage>159</fpage><pub-id pub-id-type="doi">10.3389/fnmol.2019.00159</pub-id><?supplied-pmid 31316347?><pub-id pub-id-type="pmid">31316347</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adanyeguh</surname><given-names>IM</given-names></name><name><surname>Henry</surname><given-names>P-G</given-names></name><name><surname>Nguyen</surname><given-names>TM</given-names></name><name><surname>Rinaldi</surname><given-names>D</given-names></name><name><surname>Jauffret</surname><given-names>C</given-names></name><name><surname>Valabregue</surname><given-names>R</given-names></name><name><surname>Emir</surname><given-names>UE</given-names></name><name><surname>Deelchand</surname><given-names>DK</given-names></name><name><surname>Brice</surname><given-names>A</given-names></name><name><surname>Eberly</surname><given-names>LE</given-names></name><name><surname>&#x000d6;z</surname><given-names>G</given-names></name><name><surname>Durr</surname><given-names>A</given-names></name><name><surname>Mochel</surname><given-names>F</given-names></name></person-group><article-title>In vivo neurometabolic profiling in patients with spinocerebellar ataxia types 1, 2, 3, and 7</article-title><source>Mov Disord</source><year>2015</year><volume>30</volume><issue>5</issue><fpage>662</fpage><lpage>670</lpage><pub-id pub-id-type="doi">10.1002/mds.26181</pub-id><?supplied-pmid 25773989?><pub-id pub-id-type="pmid">25773989</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Torres-Ramos</surname><given-names>Y</given-names></name><name><surname>Montoya-Estrada</surname><given-names>A</given-names></name><name><surname>Cisneros</surname><given-names>B</given-names></name><name><surname>Tercero-P&#x000e9;rez</surname><given-names>K</given-names></name><name><surname>Le&#x000f3;n-Reyes</surname><given-names>G</given-names></name><name><surname>Leyva-Garc&#x000ed;a</surname><given-names>N</given-names></name><name><surname>Hern&#x000e1;ndez-Hern&#x000e1;ndez</surname><given-names>O</given-names></name><name><surname>Maga&#x000f1;a</surname><given-names>JJ</given-names></name></person-group><article-title>Oxidative stress in spinocerebellar ataxia type 7 is associated with disease severity</article-title><source>Cerebellum</source><year>2018</year><volume>17</volume><issue>5</issue><fpage>601</fpage><lpage>609</lpage><pub-id pub-id-type="doi">10.1007/s12311-018-0947-0</pub-id><?supplied-pmid 29876803?><pub-id pub-id-type="pmid">29876803</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brockmann</surname><given-names>K</given-names></name><name><surname>Reimold</surname><given-names>M</given-names></name><name><surname>Globas</surname><given-names>C</given-names></name><name><surname>Hauser</surname><given-names>TK</given-names></name><name><surname>Walter</surname><given-names>U</given-names></name><name><surname>Machulla</surname><given-names>H-J</given-names></name><name><surname>Rolfs</surname><given-names>A</given-names></name><name><surname>Sch&#x000f6;ls</surname><given-names>L</given-names></name></person-group><article-title>PET and MRI reveal early evidence of neurodegeneration in spinocerebellar ataxia type 17</article-title><source>J Nucl Med</source><year>2012</year><volume>53</volume><issue>7</issue><fpage>1074</fpage><lpage>1080</lpage><pub-id pub-id-type="doi">10.2967/jnumed.111.101543</pub-id><?supplied-pmid 22653791?><pub-id pub-id-type="pmid">22653791</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mundwiler</surname><given-names>A</given-names></name><name><surname>Shakkottai</surname><given-names>VG</given-names></name></person-group><article-title>Autosomal-dominant cerebellar ataxias</article-title><source>Handb Clin Neurol</source><year>2018</year><volume>147</volume><fpage>173</fpage><lpage>185</lpage><pub-id pub-id-type="doi">10.1016/B978-0-444-63233-3.00012-9</pub-id><?supplied-pmid 29325610?><pub-id pub-id-type="pmid">29325610</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jen</surname><given-names>JC</given-names></name><name><surname>Graves</surname><given-names>TD</given-names></name><name><surname>Hess</surname><given-names>EJ</given-names></name><name><surname>Hanna</surname><given-names>MG</given-names></name><name><surname>Griggs</surname><given-names>RC</given-names></name><name><surname>Baloh</surname><given-names>RW</given-names></name></person-group><article-title>CINCH investigators. Primary episodic ataxias: diagnosis, pathogenesis and treatment</article-title><source>Brain.</source><year>2007</year><volume>130</volume><issue>10</issue><fpage>2484</fpage><lpage>2493</lpage><pub-id pub-id-type="doi">10.1093/brain/awm126</pub-id><?supplied-pmid 17575281?><pub-id pub-id-type="pmid">17575281</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Choi</surname><given-names>K-D</given-names></name><name><surname>Choi</surname><given-names>J-H</given-names></name></person-group><article-title>Episodic ataxias: clinical and genetic features</article-title><source>J Mov Disord</source><year>2016</year><volume>9</volume><issue>3</issue><fpage>129</fpage><lpage>135</lpage><pub-id pub-id-type="doi">10.14802/jmd.16028</pub-id><?supplied-pmid 27667184?><pub-id pub-id-type="pmid">27667184</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Hasan</surname><given-names>SM</given-names></name><name><surname>D&#x02019;Adamo</surname><given-names>MC</given-names></name></person-group><person-group person-group-type="editor"><name><surname>Adam</surname><given-names>MP</given-names></name><name><surname>Ardinger</surname><given-names>HH</given-names></name><name><surname>Pagon</surname><given-names>RA</given-names></name><name><surname>Wallace</surname><given-names>SE</given-names></name></person-group><article-title>Episodic ataxia type 1</article-title><source>GeneReviews<sup>&#x000ae;</sup> [Internet]</source><year>2018</year><publisher-loc>Seattle</publisher-loc><publisher-name>University of Washington</publisher-name></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mantuano</surname><given-names>E</given-names></name><name><surname>Veneziano</surname><given-names>L</given-names></name><name><surname>Spadaro</surname><given-names>M</given-names></name><name><surname>Giunti</surname><given-names>P</given-names></name><name><surname>Guida</surname><given-names>S</given-names></name><name><surname>Leggio</surname><given-names>MG</given-names></name><name><surname>Verriello</surname><given-names>L</given-names></name><name><surname>Wood</surname><given-names>N</given-names></name><name><surname>Jodice</surname><given-names>C</given-names></name><name><surname>Frontali</surname><given-names>M</given-names></name></person-group><article-title>Clusters of non-truncating mutations of P/Q type Ca<sup>2+</sup> channel subunit Ca<sub>v</sub>2. 1 causing episodic ataxia 2</article-title><source>J Med Genet.</source><year>2004</year><volume>41</volume><issue>6</issue><fpage>e82</fpage><pub-id pub-id-type="doi">10.1136/jmg.2003.015396</pub-id><?supplied-pmid 15173248?><pub-id pub-id-type="pmid">15173248</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Spacey</surname><given-names>S</given-names></name></person-group><person-group person-group-type="editor"><name><surname>Adam</surname><given-names>MP</given-names></name><name><surname>Ardinger</surname><given-names>HH</given-names></name><name><surname>Pagon</surname><given-names>RA</given-names></name><name><surname>Wallace</surname><given-names>SE</given-names></name></person-group><article-title>Episodic ataxia type 2</article-title><source>GeneReviews<sup>&#x000ae;</sup> [Internet]</source><year>2015</year><publisher-loc>Seattle</publisher-loc><publisher-name>University of Washington</publisher-name></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mascalchi</surname><given-names>M</given-names></name><name><surname>Salvi</surname><given-names>F</given-names></name><name><surname>Piacentini</surname><given-names>S</given-names></name><name><surname>Bartolozzi</surname><given-names>C</given-names></name></person-group><article-title>Friedreich&#x02019;s ataxia: MR findings involving the cervical portion of the spinal cord</article-title><source>AJR Am J Roentgenol</source><year>1994</year><volume>163</volume><issue>1</issue><fpage>187</fpage><lpage>191</lpage><pub-id pub-id-type="doi">10.2214/ajr.163.1.8010211</pub-id><?supplied-pmid 8010211?><pub-id pub-id-type="pmid">8010211</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Campuzano</surname><given-names>V</given-names></name><name><surname>Montermini</surname><given-names>L</given-names></name><name><surname>Molto</surname><given-names>MD</given-names></name><name><surname>Pianese</surname><given-names>L</given-names></name><name><surname>Coss&#x000e9;e</surname><given-names>M</given-names></name><name><surname>Cavalcanti</surname><given-names>F</given-names></name><name><surname>Monros</surname><given-names>E</given-names></name><name><surname>Rodius</surname><given-names>F</given-names></name><name><surname>Duclos</surname><given-names>F</given-names></name><name><surname>Monticelli</surname><given-names>A</given-names></name><name><surname>Zara</surname><given-names>F</given-names></name><name><surname>Ca&#x000f1;izares</surname><given-names>J</given-names></name><name><surname>Koutnikova</surname><given-names>H</given-names></name><name><surname>Bidichandani</surname><given-names>SI</given-names></name><name><surname>Gellera</surname><given-names>C</given-names></name><name><surname>Brice</surname><given-names>A</given-names></name><name><surname>Trouillas</surname><given-names>P</given-names></name><name><surname>De Michele</surname><given-names>G</given-names></name><name><surname>Filla</surname><given-names>A</given-names></name><name><surname>De Frutos</surname><given-names>R</given-names></name><name><surname>Palau</surname><given-names>F</given-names></name><name><surname>Patel</surname><given-names>PI</given-names></name><name><surname>Di Donato</surname><given-names>S</given-names></name><name><surname>Mandel</surname><given-names>J-L</given-names></name><name><surname>Cocozza</surname><given-names>S</given-names></name><name><surname>Koenig</surname><given-names>M</given-names></name><name><surname>Pandolfo</surname><given-names>M</given-names></name></person-group><article-title>Friedreich&#x02019;s ataxia: autosomal recessive disease caused by an intronic GAA triplet repeat expansion</article-title><source>Science</source><year>1996</year><volume>271</volume><issue>5254</issue><fpage>1423</fpage><lpage>1427</lpage><pub-id pub-id-type="doi">10.1126/science.271.5254.1423</pub-id><?supplied-pmid 8596916?><pub-id pub-id-type="pmid">8596916</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McKinnon</surname><given-names>PJ</given-names></name></person-group><article-title>ATM and the molecular pathogenesis of ataxia telangiectasia</article-title><source>Annu Rev Pathol</source><year>2012</year><volume>7</volume><fpage>303</fpage><lpage>321</lpage><pub-id pub-id-type="doi">10.1146/annurev-pathol-011811-132509</pub-id><?supplied-pmid 22035194?><pub-id pub-id-type="pmid">22035194</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sahama</surname><given-names>I</given-names></name><name><surname>Sinclair</surname><given-names>K</given-names></name><name><surname>Pannek</surname><given-names>K</given-names></name><name><surname>Lavin</surname><given-names>M</given-names></name><name><surname>Rose</surname><given-names>S</given-names></name></person-group><article-title>Radiological imaging in ataxia telangiectasia: a review</article-title><source>Cerebellum</source><year>2014</year><volume>13</volume><issue>4</issue><fpage>521</fpage><lpage>530</lpage><pub-id pub-id-type="doi">10.1007/s12311-014-0557-4</pub-id><?supplied-pmid 24683014?><pub-id pub-id-type="pmid">24683014</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rothblum-Oviatt</surname><given-names>C</given-names></name><name><surname>Wright</surname><given-names>J</given-names></name><name><surname>Lefton-Greif</surname><given-names>MA</given-names></name><name><surname>McGrath-Morrow</surname><given-names>SA</given-names></name><name><surname>Crawford</surname><given-names>TO</given-names></name><name><surname>Lederman</surname><given-names>HM</given-names></name></person-group><article-title>Ataxia telangiectasia: a review</article-title><source>Orphanet J Rare Dis</source><year>2016</year><volume>11</volume><fpage>159</fpage><pub-id pub-id-type="doi">10.1186/s13023-016-0543-7</pub-id><?supplied-pmid 27884168?><pub-id pub-id-type="pmid">27884168</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anheim</surname><given-names>M</given-names></name><name><surname>Monga</surname><given-names>B</given-names></name><name><surname>Fleury</surname><given-names>M</given-names></name><name><surname>Charles</surname><given-names>P</given-names></name><name><surname>Barbot</surname><given-names>C</given-names></name><name><surname>Salih</surname><given-names>M</given-names></name><name><surname>Delaunoy</surname><given-names>JP</given-names></name><name><surname>Fritsch</surname><given-names>M</given-names></name><name><surname>Arning</surname><given-names>L</given-names></name><name><surname>Synofzik</surname><given-names>M</given-names></name><name><surname>Sch&#x000f6;ls</surname><given-names>L</given-names></name><name><surname>Sequeiros</surname><given-names>J</given-names></name><name><surname>Goizet</surname><given-names>C</given-names></name><name><surname>Marelli</surname><given-names>C</given-names></name><name><surname>Le Ber</surname><given-names>I</given-names></name><name><surname>Koht</surname><given-names>J</given-names></name><name><surname>Gazulla</surname><given-names>J</given-names></name><name><surname>De Bleecker</surname><given-names>J</given-names></name><name><surname>Mukhtar</surname><given-names>M</given-names></name><name><surname>Drouot</surname><given-names>N</given-names></name><name><surname>Ali-Pacha</surname><given-names>L</given-names></name><name><surname>Benhassine</surname><given-names>T</given-names></name><name><surname>Chbicheb</surname><given-names>M</given-names></name><name><surname>M&#x02019;Zahem</surname><given-names>A</given-names></name><name><surname>Hamri</surname><given-names>A</given-names></name><name><surname>Chabrol</surname><given-names>B</given-names></name><name><surname>Pouget</surname><given-names>J</given-names></name><name><surname>Murphy</surname><given-names>R</given-names></name><name><surname>Watanabe</surname><given-names>M</given-names></name><name><surname>Coutinho</surname><given-names>P</given-names></name><name><surname>Tazir</surname><given-names>M</given-names></name><name><surname>Durr</surname><given-names>A</given-names></name><name><surname>Brice</surname><given-names>A</given-names></name><name><surname>Tranchant</surname><given-names>C</given-names></name><name><surname>Koenig</surname><given-names>M</given-names></name></person-group><article-title>Ataxia with oculomotor apraxia type 2: clinical, biological and genotype/phenotype correlation study of a cohort of 90 patients</article-title><source>Brain</source><year>2009</year><volume>132</volume><issue>10</issue><fpage>2688</fpage><lpage>2698</lpage><pub-id pub-id-type="doi">10.1093/brain/awp211</pub-id><?supplied-pmid 19696032?><pub-id pub-id-type="pmid">19696032</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Coutinho</surname><given-names>P</given-names></name><name><surname>Barbot</surname><given-names>C</given-names></name></person-group><person-group person-group-type="editor"><name><surname>Adam</surname><given-names>MP</given-names></name><name><surname>Ardinger</surname><given-names>HH</given-names></name><name><surname>Pagon</surname><given-names>RA</given-names></name><name><surname>Wallace</surname><given-names>SE</given-names></name></person-group><article-title>Ataxia with oculomotor apraxia type 1</article-title><source>GeneReviews<sup>&#x000ae;</sup> [Internet]</source><year>2015</year><publisher-loc>Seattle</publisher-loc><publisher-name>University of Washington</publisher-name></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Moreira</surname><given-names>M-C</given-names></name><name><surname>Koenig</surname><given-names>M</given-names></name></person-group><person-group person-group-type="editor"><name><surname>Adam</surname><given-names>MP</given-names></name><name><surname>Ardinger</surname><given-names>HH</given-names></name><name><surname>Pagon</surname><given-names>RA</given-names></name><name><surname>Wallace</surname><given-names>SE</given-names></name></person-group><article-title>Ataxia with oculomotor apraxia type 2</article-title><source>GeneReviews<sup>&#x000ae;</sup> [Internet]</source><year>2018</year><publisher-loc>Seattle</publisher-loc><publisher-name>University of Washington</publisher-name></element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leehey</surname><given-names>MA</given-names></name></person-group><article-title>Fragile X-associated tremor/ataxia syndrome: clinical phenotype, diagnosis, and treatment</article-title><source>J Investig Med</source><year>2009</year><volume>57</volume><issue>8</issue><fpage>830</fpage><lpage>836</lpage><pub-id pub-id-type="doi">10.2310/JIM.0b013e3181af59c4</pub-id><?supplied-pmid 19574929?><pub-id pub-id-type="pmid">19574929</pub-id></element-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Currie</surname><given-names>S</given-names></name><name><surname>Hadjivassiliou</surname><given-names>M</given-names></name><name><surname>Craven</surname><given-names>IJ</given-names></name><name><surname>Wilkinson</surname><given-names>ID</given-names></name><name><surname>Griffiths</surname><given-names>PD</given-names></name><name><surname>Hoggard</surname><given-names>N</given-names></name></person-group><article-title>Magnetic resonance imaging biomarkers in patients with progressive ataxia: current status and future direction</article-title><source>Cerebellum</source><year>2013</year><volume>12</volume><issue>2</issue><fpage>245</fpage><lpage>266</lpage><pub-id pub-id-type="doi">10.1007/s12311-012-0405-3</pub-id><?supplied-pmid 22828959?><pub-id pub-id-type="pmid">22828959</pub-id></element-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Tassone</surname><given-names>F</given-names></name><name><surname>Hall</surname><given-names>DA</given-names></name></person-group><source>FXTAS, FXPOI, and other premutation disorders</source><year>2016</year><edition>2</edition><publisher-loc>Cham</publisher-loc><publisher-name>Springer</publisher-name></element-citation></ref><ref id="CR38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Braga-Neto</surname><given-names>P</given-names></name><name><surname>Pedroso</surname><given-names>JL</given-names></name><name><surname>Kuo</surname><given-names>S-H</given-names></name><name><surname>Marcondes Junior</surname><given-names>CF</given-names></name><name><surname>Teive</surname><given-names>HAG</given-names></name><name><surname>Barsottini</surname><given-names>OGP</given-names></name></person-group><article-title>Current concepts in the treatment of hereditary ataxias</article-title><source>Arq Neuropsiquiatr</source><year>2016</year><volume>74</volume><issue>3</issue><fpage>244</fpage><lpage>252</lpage><pub-id pub-id-type="doi">10.1590/0004-282X20160038</pub-id><?supplied-pmid 27050855?><pub-id pub-id-type="pmid">27050855</pub-id></element-citation></ref><ref id="CR39"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sullivan</surname><given-names>R</given-names></name><name><surname>Yau</surname><given-names>WY</given-names></name><name><surname>O&#x02019;Connor</surname><given-names>E</given-names></name><name><surname>Houlden</surname><given-names>H</given-names></name></person-group><article-title>Spinocerebellar ataxia: an update</article-title><source>J Neurol</source><year>2019</year><volume>266</volume><issue>2</issue><fpage>533</fpage><lpage>544</lpage><pub-id pub-id-type="doi">10.1007/s00415-018-9076-4</pub-id><?supplied-pmid 30284037?><pub-id pub-id-type="pmid">30284037</pub-id></element-citation></ref><ref id="CR40"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schniepp</surname><given-names>R</given-names></name><name><surname>Strupp</surname><given-names>M</given-names></name><name><surname>Wuehr</surname><given-names>M</given-names></name><name><surname>Jahn</surname><given-names>K</given-names></name><name><surname>Dieterich</surname><given-names>M</given-names></name><name><surname>Brandt</surname><given-names>T</given-names></name><name><surname>Feil</surname><given-names>K</given-names></name></person-group><article-title>Acetyl-DL-leucine improves gait variability in patients with cerebellar ataxia&#x02014;a case series</article-title><source>Cerebellum Ataxias</source><year>2016</year><volume>3</volume><fpage>8</fpage><pub-id pub-id-type="doi">10.1186/s40673-016-0046-2</pub-id><?supplied-pmid 27073690?><pub-id pub-id-type="pmid">27073690</pub-id></element-citation></ref><ref id="CR41"><label>41.</label><mixed-citation publication-type="other">National Library of Medicine (U.S.). N-Acetyl-L-Leucine for Ataxia-Telangiectasia (A-T). https://clinicaltrials.gov/ct2/show/NCT03759678 (2018). NLM identifier: NCT03759678. Accessed 25 July 2020</mixed-citation></ref><ref id="CR42"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Butler</surname><given-names>MS</given-names></name><name><surname>Fontaine</surname><given-names>F</given-names></name><name><surname>Cooper</surname><given-names>MA</given-names></name></person-group><article-title>Natural product libraries: assembly, maintenance, and screening</article-title><source>Planta Med</source><year>2014</year><volume>80</volume><issue>14</issue><fpage>1161</fpage><lpage>1170</lpage><pub-id pub-id-type="doi">10.1055/s-0033-1360109</pub-id><?supplied-pmid 24310213?><pub-id pub-id-type="pmid">24310213</pub-id></element-citation></ref><ref id="CR43"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pohl</surname><given-names>F</given-names></name><name><surname>Kong Thoo Lin</surname><given-names>P</given-names></name></person-group><article-title>The potential use of plant natural products and plant extracts with antioxidant properties for the prevention/treatment of neurodegenerative diseases: in vitro, in vivo and clinical trials</article-title><source>Molecules.</source><year>2018</year><volume>23</volume><issue>12</issue><fpage>3283</fpage><pub-id pub-id-type="doi">10.3390/molecules23123283</pub-id></element-citation></ref><ref id="CR44"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ayaz</surname><given-names>M</given-names></name><name><surname>Ullah</surname><given-names>F</given-names></name><name><surname>Sadiq</surname><given-names>A</given-names></name><name><surname>Kim</surname><given-names>MO</given-names></name><name><surname>Ali</surname><given-names>T</given-names></name></person-group><article-title>Natural products-based drugs: potential therapeutics against Alzheimer&#x02019;s disease and other neurological disorders</article-title><source>Front Pharmacol</source><year>2019</year><volume>10</volume><fpage>1417</fpage><pub-id pub-id-type="doi">10.3389/fphar.2019.01417</pub-id><?supplied-pmid 31849668?><pub-id pub-id-type="pmid">31849668</pub-id></element-citation></ref><ref id="CR45"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clardy</surname><given-names>J</given-names></name><name><surname>Walsh</surname><given-names>C</given-names></name></person-group><article-title>Lessons from natural molecules</article-title><source>Nature</source><year>2004</year><volume>432</volume><issue>7019</issue><fpage>829</fpage><lpage>837</lpage><pub-id pub-id-type="doi">10.1038/nature03194</pub-id><?supplied-pmid 15602548?><pub-id pub-id-type="pmid">15602548</pub-id></element-citation></ref><ref id="CR46"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guo</surname><given-names>Z</given-names></name></person-group><article-title>The modification of natural products for medical use</article-title><source>Acta Pharm Sin B</source><year>2017</year><volume>7</volume><issue>2</issue><fpage>119</fpage><lpage>136</lpage><pub-id pub-id-type="doi">10.1016/j.apsb.2016.06.003</pub-id><?supplied-pmid 28303218?><pub-id pub-id-type="pmid">28303218</pub-id></element-citation></ref><ref id="CR47"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harvey</surname><given-names>AL</given-names></name><name><surname>Edrada-Ebel</surname><given-names>R</given-names></name><name><surname>Quinn</surname><given-names>RJ</given-names></name></person-group><article-title>The re-emergence of natural products for drug discovery in the genomics era</article-title><source>Nat Rev Drug Discov</source><year>2015</year><volume>14</volume><issue>2</issue><fpage>111</fpage><lpage>129</lpage><pub-id pub-id-type="doi">10.1038/nrd4510</pub-id><?supplied-pmid 25614221?><pub-id pub-id-type="pmid">25614221</pub-id></element-citation></ref><ref id="CR48"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>R</given-names></name><name><surname>Zhu</surname><given-names>X</given-names></name><name><surname>Bai</surname><given-names>H</given-names></name><name><surname>Ning</surname><given-names>K</given-names></name></person-group><article-title>Network pharmacology databases for traditional Chinese medicine: review and assessment</article-title><source>Front Pharmacol</source><year>2019</year><volume>10</volume><fpage>123</fpage><pub-id pub-id-type="doi">10.3389/fphar.2019.00123</pub-id><?supplied-pmid 30846939?><pub-id pub-id-type="pmid">30846939</pub-id></element-citation></ref><ref id="CR49"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Decker</surname><given-names>M</given-names></name></person-group><article-title>Multi-target compounds acting in the central nervous system designed from natural products</article-title><source>Curr Med Chem</source><year>2013</year><volume>20</volume><issue>13</issue><fpage>1673</fpage><lpage>1685</lpage><pub-id pub-id-type="doi">10.2174/0929867311320130007</pub-id><?supplied-pmid 23410166?><pub-id pub-id-type="pmid">23410166</pub-id></element-citation></ref><ref id="CR50"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koeberle</surname><given-names>A</given-names></name><name><surname>Werz</surname><given-names>O</given-names></name></person-group><article-title>Multi-target approach for natural products in inflammation</article-title><source>Drug Discov Today</source><year>2014</year><volume>19</volume><issue>12</issue><fpage>1871</fpage><lpage>1882</lpage><pub-id pub-id-type="doi">10.1016/j.drudis.2014.08.006</pub-id><?supplied-pmid 25172801?><pub-id pub-id-type="pmid">25172801</pub-id></element-citation></ref><ref id="CR51"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Salvador-Reyes</surname><given-names>LA</given-names></name><name><surname>Luesch</surname><given-names>H</given-names></name></person-group><article-title>Biological targets and mechanisms of action of natural products from marine cyanobacteria</article-title><source>Nat Prod Rep</source><year>2015</year><volume>32</volume><issue>3</issue><fpage>478</fpage><lpage>503</lpage><pub-id pub-id-type="doi">10.1039/c4np00104d</pub-id><?supplied-pmid 25571978?><pub-id pub-id-type="pmid">25571978</pub-id></element-citation></ref><ref id="CR52"><label>52.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Lozano</surname><given-names>F</given-names></name></person-group><person-group person-group-type="editor"><name><surname>Lin</surname><given-names>Y-C</given-names></name><name><surname>Hsu</surname><given-names>ES-Z</given-names></name></person-group><article-title>Basic theories of traditional Chinese medicine</article-title><source>Acupuncture for Pain Management</source><year>2014</year><publisher-loc>New York</publisher-loc><publisher-name>Springer</publisher-name></element-citation></ref><ref id="CR53"><label>53.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Marshall</surname><given-names>AC</given-names></name></person-group><person-group person-group-type="editor"><name><surname>Hock</surname><given-names>F</given-names></name><name><surname>Gralinski</surname><given-names>M</given-names></name></person-group><article-title>Traditional Chinese medicine and clinical pharmacology</article-title><source>Drug discovery and evaluation: methods in clinical pharmacology</source><year>2020</year><publisher-loc>Cham</publisher-loc><publisher-name>Springer</publisher-name><fpage>455</fpage><lpage>82</lpage></element-citation></ref><ref id="CR54"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>T-Y</given-names></name><name><surname>Chen</surname><given-names>C-P</given-names></name><name><surname>Jinn</surname><given-names>T-R</given-names></name></person-group><article-title>Traditional Chinese medicines and Alzheimer&#x02019;s disease</article-title><source>Taiwan J Obstet Gynecol</source><year>2011</year><volume>50</volume><issue>2</issue><fpage>131</fpage><lpage>135</lpage><pub-id pub-id-type="doi">10.1016/j.tjog.2011.04.004</pub-id><?supplied-pmid 21791295?><pub-id pub-id-type="pmid">21791295</pub-id></element-citation></ref><ref id="CR55"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>I-C</given-names></name><name><surname>Chang</surname><given-names>C-N</given-names></name><name><surname>Chen</surname><given-names>W-L</given-names></name><name><surname>Lin</surname><given-names>T-H</given-names></name><name><surname>Chao</surname><given-names>C-Y</given-names></name><name><surname>Lin</surname><given-names>C-H</given-names></name><name><surname>Lin</surname><given-names>H-Y</given-names></name><name><surname>Cheng</surname><given-names>M-L</given-names></name><name><surname>Chiang</surname><given-names>M-C</given-names></name><name><surname>Lin</surname><given-names>J-Y</given-names></name><name><surname>Wu</surname><given-names>Y-R</given-names></name><name><surname>Lee-Chen</surname><given-names>G-J</given-names></name><name><surname>Chen</surname><given-names>C-M</given-names></name></person-group><article-title>Targeting ubiquitin proteasome pathway with traditional Chinese medicine for treatment of spinocerebellar ataxia type 3</article-title><source>Am J Chin Med.</source><year>2019</year><volume>47</volume><issue>1</issue><fpage>63</fpage><lpage>95</lpage><pub-id pub-id-type="doi">10.1142/s0192415x19500046</pub-id><?supplied-pmid 30612452?><pub-id pub-id-type="pmid">30612452</pub-id></element-citation></ref><ref id="CR56"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>I-C</given-names></name><name><surname>Chang</surname><given-names>K-H</given-names></name><name><surname>Chen</surname><given-names>Y-J</given-names></name><name><surname>Chen</surname><given-names>Y-C</given-names></name><name><surname>Lee-Chen</surname><given-names>G-J</given-names></name><name><surname>Chen</surname><given-names>C-M</given-names></name></person-group><article-title><italic>Pueraria lobata</italic> and daidzein reduce cytotoxicity by enhancing ubiquitin-proteasome system function in SCA3-iPSC-derived neurons</article-title><source>Oxid Med Cell Longev</source><year>2019</year><volume>2019</volume><fpage>8130481</fpage><pub-id pub-id-type="doi">10.1155/2019/8130481</pub-id><?supplied-pmid 31687087?><pub-id pub-id-type="pmid">31687087</pub-id></element-citation></ref><ref id="CR57"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chou</surname><given-names>A-H</given-names></name><name><surname>Chen</surname><given-names>Y-L</given-names></name><name><surname>Chiu</surname><given-names>C-C</given-names></name><name><surname>Yuan</surname><given-names>S-J</given-names></name><name><surname>Weng</surname><given-names>Y-H</given-names></name><name><surname>Yeh</surname><given-names>T-H</given-names></name><name><surname>Lin</surname><given-names>Y-L</given-names></name><name><surname>Fang</surname><given-names>J-M</given-names></name><name><surname>Wang</surname><given-names>H-L</given-names></name></person-group><article-title>T1-11 and JMF1907 ameliorate polyglutamine-expanded ataxin-3-induced neurodegeneration, transcriptional dysregulation and symptoms of ataxia in the SCA3 transgenic mouse</article-title><source>Neuropharmacology</source><year>2015</year><volume>99</volume><fpage>308</fpage><lpage>317</lpage><pub-id pub-id-type="doi">10.1016/j.neuropharm.2015.08.009</pub-id><?supplied-pmid 26254860?><pub-id pub-id-type="pmid">26254860</pub-id></element-citation></ref><ref id="CR58"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chang</surname><given-names>K-H</given-names></name><name><surname>Chen</surname><given-names>W-L</given-names></name><name><surname>Wu</surname><given-names>Y-R</given-names></name><name><surname>Lin</surname><given-names>T-H</given-names></name><name><surname>Wu</surname><given-names>Y-C</given-names></name><name><surname>Chao</surname><given-names>C-Y</given-names></name><name><surname>Lin</surname><given-names>J-Y</given-names></name><name><surname>Lee</surname><given-names>L-C</given-names></name><name><surname>Chen</surname><given-names>Y-C</given-names></name><name><surname>Lee-Chen</surname><given-names>G-J</given-names></name><name><surname>Chen</surname><given-names>C-M</given-names></name></person-group><article-title>Aqueous extract of <italic>Gardenia jasminoides</italic> targeting oxidative stress to reduce polyQ aggregation in cell models of spinocerebellar ataxia 3</article-title><source>Neuropharmacology</source><year>2014</year><volume>81</volume><fpage>166</fpage><lpage>175</lpage><pub-id pub-id-type="doi">10.1016/j.neuropharm.2014.01.032</pub-id><?supplied-pmid 24486383?><pub-id pub-id-type="pmid">24486383</pub-id></element-citation></ref><ref id="CR59"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>C-M</given-names></name><name><surname>Weng</surname><given-names>Y-T</given-names></name><name><surname>Chen</surname><given-names>W-L</given-names></name><name><surname>Lin</surname><given-names>T-H</given-names></name><name><surname>Chao</surname><given-names>C-Y</given-names></name><name><surname>Lin</surname><given-names>C-H</given-names></name><name><surname>Chen</surname><given-names>I-C</given-names></name><name><surname>Lee</surname><given-names>L-C</given-names></name><name><surname>Lin</surname><given-names>H-Y</given-names></name><name><surname>Wu</surname><given-names>Y-R</given-names></name><name><surname>Chen</surname><given-names>Y-C</given-names></name><name><surname>Chang</surname><given-names>K-H</given-names></name><name><surname>Tang</surname><given-names>H-Y</given-names></name><name><surname>Cheng</surname><given-names>M-L</given-names></name><name><surname>Lee-Chen</surname><given-names>G-J</given-names></name><name><surname>Lin</surname><given-names>J-Y</given-names></name></person-group><article-title>Aqueous extract of <italic>Glycyrrhiza inflata</italic> inhibits aggregation by upregulating PPARGC1A and NFE2L2&#x02013;ARE pathways in cell models of spinocerebellar ataxia 3</article-title><source>Free Radic Biol Med</source><year>2014</year><volume>71</volume><fpage>339</fpage><lpage>350</lpage><pub-id pub-id-type="doi">10.1016/j.freeradbiomed.2014.03.023</pub-id><?supplied-pmid 24675225?><pub-id pub-id-type="pmid">24675225</pub-id></element-citation></ref><ref id="CR60"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chang</surname><given-names>K-H</given-names></name><name><surname>Chen</surname><given-names>W-L</given-names></name><name><surname>Lee</surname><given-names>L-C</given-names></name><name><surname>Lin</surname><given-names>C-H</given-names></name><name><surname>Kung</surname><given-names>P-J</given-names></name><name><surname>Lin</surname><given-names>T-H</given-names></name><name><surname>Wu</surname><given-names>Y-C</given-names></name><name><surname>Wu</surname><given-names>Y-R</given-names></name><name><surname>Chen</surname><given-names>Y-C</given-names></name><name><surname>Lee</surname><given-names>G-J</given-names></name><name><surname>Chen</surname><given-names>C-M</given-names></name></person-group><article-title>Aqueous extract of <italic>Paeonia lactiflora</italic> and paeoniflorin as aggregation reducers targeting chaperones in cell models of spinocerebellar ataxia 3</article-title><source>Evid Based Complement Alternat Med</source><year>2013</year><volume>2013</volume><fpage>471659</fpage><pub-id pub-id-type="doi">10.1155/2013/471659</pub-id><?supplied-pmid 23533486?><pub-id pub-id-type="pmid">23533486</pub-id></element-citation></ref><ref id="CR61"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pohl</surname><given-names>F</given-names></name><name><surname>Teixeira-Castro</surname><given-names>A</given-names></name><name><surname>Costa</surname><given-names>MD</given-names></name><name><surname>Lindsay</surname><given-names>V</given-names></name><name><surname>Fi&#x000fa;za-Fernandes</surname><given-names>J</given-names></name><name><surname>Goua</surname><given-names>M</given-names></name><name><surname>Bermano</surname><given-names>G</given-names></name><name><surname>Russell</surname><given-names>W</given-names></name><name><surname>Maciel</surname><given-names>P</given-names></name><name><surname>Kong Thoo Lin</surname><given-names>P</given-names></name></person-group><article-title>Kong Thoo Lin P. GST-4-dependent suppression of neurodegeneration in C. elegans models of Parkinson&#x02019;s and Machado-Joseph disease by rapeseed pomace extract supplementation</article-title><source>Front Neurosci.</source><year>2019</year><volume>13</volume><fpage>1091</fpage><pub-id pub-id-type="doi">10.3389/fnins.2019.01091</pub-id><?supplied-pmid 31680826?><pub-id pub-id-type="pmid">31680826</pub-id></element-citation></ref><ref id="CR62"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>D-S</given-names></name><name><surname>Lin</surname><given-names>H-Y</given-names></name><name><surname>Lee-Chen</surname><given-names>G-J</given-names></name><name><surname>Hsieh-Li</surname><given-names>H-M</given-names></name><name><surname>Wu</surname><given-names>C-H</given-names></name><name><surname>Lin</surname><given-names>J-Y</given-names></name></person-group><article-title>Treatment with a <italic>Ginkgo biloba</italic> extract, EGb 761, inhibits excitotoxicity in an animal model of spinocerebellar ataxia type 17</article-title><source>Drug Des Devel Ther</source><year>2016</year><volume>10</volume><fpage>723</fpage><lpage>731</lpage><pub-id pub-id-type="doi">10.2147/DDDT.S98156</pub-id><?supplied-pmid 26937174?><pub-id pub-id-type="pmid">26937174</pub-id></element-citation></ref><ref id="CR63"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Okabe</surname><given-names>T</given-names></name><name><surname>Fujisawa</surname><given-names>M</given-names></name><name><surname>Sekiya</surname><given-names>T</given-names></name><name><surname>Ichikawa</surname><given-names>Y</given-names></name><name><surname>Goto</surname><given-names>J</given-names></name></person-group><article-title>Successful treatment of spinocerebellar ataxia 6 with medicinal herbs</article-title><source>Geriatr Gerontol Int</source><year>2007</year><volume>7</volume><issue>2</issue><fpage>195</fpage><lpage>197</lpage><pub-id pub-id-type="doi">10.1111/j.1447-0594.2007.00378.x</pub-id></element-citation></ref><ref id="CR64"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Okabe</surname><given-names>T</given-names></name></person-group><article-title>Remission induction of spinocerebellar ataxia 6 with medicinal herbs</article-title><source>J Aging Neuro Psychol.</source><year>2018</year><pub-id pub-id-type="doi">10.29011/janp-108.100008</pub-id></element-citation></ref><ref id="CR65"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>C-M</given-names></name><name><surname>Chen</surname><given-names>W-L</given-names></name><name><surname>Hung</surname><given-names>C-T</given-names></name><name><surname>Lin</surname><given-names>T-H</given-names></name><name><surname>Lee</surname><given-names>M-C</given-names></name><name><surname>Chen</surname><given-names>I-C</given-names></name><name><surname>Lin</surname><given-names>C-H</given-names></name><name><surname>Chao</surname><given-names>C-Y</given-names></name><name><surname>Wu</surname><given-names>Y-R</given-names></name><name><surname>Chang</surname><given-names>K-H</given-names></name><name><surname>Hsieh-Li</surname><given-names>H-M</given-names></name><name><surname>Lee-Chen</surname><given-names>G-J</given-names></name></person-group><article-title>Shaoyao Gancao Tang (SG-Tang), a formulated Chinese medicine, reduces aggregation and exerts neuroprotection in spinocerebellar ataxia type 17 (SCA17) cell and mouse models</article-title><source>Aging</source><year>2019</year><volume>11</volume><issue>3</issue><fpage>986</fpage><lpage>1007</lpage><pub-id pub-id-type="doi">10.18632/aging.101804</pub-id><?supplied-pmid 30760647?><pub-id pub-id-type="pmid">30760647</pub-id></element-citation></ref><ref id="CR66"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lew</surname><given-names>S-Y</given-names></name><name><surname>Yow</surname><given-names>Y-Y</given-names></name><name><surname>Lim</surname><given-names>L-W</given-names></name><name><surname>Wong</surname><given-names>K-H</given-names></name></person-group><article-title>Antioxidant-mediated protective role of <italic>Hericium erinaceus</italic> (Bull.: Fr.) Pers. against oxidative damage in fibroblasts from Friedreich&#x02019;s ataxia patient</article-title><source>Food Sci Technol.</source><year>2020</year><volume>40</volume><issue>Suppl 1</issue><fpage>264</fpage><lpage>272</lpage><pub-id pub-id-type="doi">10.1590/fst.09919</pub-id></element-citation></ref><ref id="CR67"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McIntosh</surname><given-names>CS</given-names></name><name><surname>Aung-Htut</surname><given-names>MT</given-names></name><name><surname>Fletcher</surname><given-names>S</given-names></name><name><surname>Wilton</surname><given-names>SD</given-names></name></person-group><article-title>Polyglutamine ataxias: from clinical and molecular features to current therapeutic strategies</article-title><source>J Genet Syndr Gene Ther</source><year>2017</year><volume>8</volume><issue>2</issue><fpage>1</fpage><lpage>17</lpage><pub-id pub-id-type="doi">10.4172/2157-7412.1000319</pub-id></element-citation></ref><ref id="CR68"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Williams</surname><given-names>AJ</given-names></name><name><surname>Paulson</surname><given-names>HL</given-names></name></person-group><article-title>Polyglutamine neurodegeneration: protein misfolding revisited</article-title><source>Trends Neurosci</source><year>2008</year><volume>31</volume><issue>10</issue><fpage>521</fpage><lpage>528</lpage><pub-id pub-id-type="doi">10.1016/j.tins.2008.07.004</pub-id><?supplied-pmid 18778858?><pub-id pub-id-type="pmid">18778858</pub-id></element-citation></ref><ref id="CR69"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dantuma</surname><given-names>NP</given-names></name><name><surname>Bott</surname><given-names>LC</given-names></name></person-group><article-title>The ubiquitin-proteasome system in neurodegenerative diseases: precipitating factor, yet part of the solution</article-title><source>Front Mol Neurosci</source><year>2014</year><volume>7</volume><fpage>70</fpage><pub-id pub-id-type="doi">10.3389/fnmol.2014.00070</pub-id><?supplied-pmid 25132814?><pub-id pub-id-type="pmid">25132814</pub-id></element-citation></ref><ref id="CR70"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bader</surname><given-names>M</given-names></name><name><surname>Steller</surname><given-names>H</given-names></name></person-group><article-title>Regulation of cell death by the ubiquitin&#x02013;proteasome system</article-title><source>Curr Opin Cell Biol</source><year>2009</year><volume>21</volume><issue>6</issue><fpage>878</fpage><lpage>884</lpage><pub-id pub-id-type="doi">10.1016/j.ceb.2009.09.005</pub-id><?supplied-pmid 19850458?><pub-id pub-id-type="pmid">19850458</pub-id></element-citation></ref><ref id="CR71"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cummings</surname><given-names>CJ</given-names></name><name><surname>Reinstein</surname><given-names>E</given-names></name><name><surname>Sun</surname><given-names>Y</given-names></name><name><surname>Antalffy</surname><given-names>B</given-names></name><name><surname>Jiang</surname><given-names>Y-H</given-names></name><name><surname>Ciechanover</surname><given-names>A</given-names></name><name><surname>Orr</surname><given-names>HT</given-names></name><name><surname>Beaudet</surname><given-names>AL</given-names></name><name><surname>Zoghbi</surname><given-names>HY</given-names></name></person-group><article-title>Mutation of the E6-AP ubiquitin ligase reduces nuclear inclusion frequency while accelerating polyglutamine-induced pathology in SCA1 mice</article-title><source>Neuron</source><year>1999</year><volume>24</volume><issue>4</issue><fpage>879</fpage><lpage>892</lpage><pub-id pub-id-type="doi">10.1016/S0896-6273(00)81035-1</pub-id><?supplied-pmid 10624951?><pub-id pub-id-type="pmid">10624951</pub-id></element-citation></ref><ref id="CR72"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matilla</surname><given-names>A</given-names></name><name><surname>Gorbea</surname><given-names>C</given-names></name><name><surname>Einum</surname><given-names>DD</given-names></name><name><surname>Townsend</surname><given-names>J</given-names></name><name><surname>Michalik</surname><given-names>A</given-names></name><name><surname>van Broeckhoven</surname><given-names>C</given-names></name><name><surname>Jensen</surname><given-names>CC</given-names></name><name><surname>Murphy</surname><given-names>KJ</given-names></name><name><surname>Pt&#x000e1;cek</surname><given-names>LJ</given-names></name><name><surname>Fu</surname><given-names>Y-H</given-names></name></person-group><article-title>Association of ataxin-7 with the proteasome subunit S4 of the 19S regulatory complex</article-title><source>Hum Mol Genet</source><year>2001</year><volume>10</volume><issue>24</issue><fpage>2821</fpage><lpage>2831</lpage><pub-id pub-id-type="doi">10.1093/hmg/10.24.2821</pub-id><?supplied-pmid 11734547?><pub-id pub-id-type="pmid">11734547</pub-id></element-citation></ref><ref id="CR73"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chai</surname><given-names>Y</given-names></name><name><surname>Berke</surname><given-names>SS</given-names></name><name><surname>Cohen</surname><given-names>RE</given-names></name><name><surname>Paulson</surname><given-names>HL</given-names></name></person-group><article-title>Poly-ubiquitin binding by the polyglutamine disease protein ataxin-3 links its normal function to protein surveillance pathways</article-title><source>J Biol Chem</source><year>2004</year><volume>279</volume><issue>5</issue><fpage>3605</fpage><lpage>3611</lpage><pub-id pub-id-type="doi">10.1074/jbc.M310939200</pub-id><?supplied-pmid 14602712?><pub-id pub-id-type="pmid">14602712</pub-id></element-citation></ref><ref id="CR74"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Due&#x000f1;as</surname><given-names>AM</given-names></name><name><surname>Goold</surname><given-names>R</given-names></name><name><surname>Giunti</surname><given-names>P</given-names></name></person-group><article-title>Molecular pathogenesis of spinocerebellar ataxias</article-title><source>Brain</source><year>2006</year><volume>129</volume><issue>6</issue><fpage>1357</fpage><lpage>1370</lpage><pub-id pub-id-type="doi">10.1093/brain/awl081</pub-id><?supplied-pmid 16613893?><pub-id pub-id-type="pmid">16613893</pub-id></element-citation></ref><ref id="CR75"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Myeku</surname><given-names>N</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Figueiredo-Pereira</surname><given-names>ME</given-names></name></person-group><article-title>cAMP stimulates the ubiquitin/proteasome pathway in rat spinal cord neurons</article-title><source>Neurosci Lett</source><year>2012</year><volume>527</volume><issue>2</issue><fpage>126</fpage><lpage>131</lpage><pub-id pub-id-type="doi">10.1016/j.neulet.2012.08.051</pub-id><?supplied-pmid 22982149?><pub-id pub-id-type="pmid">22982149</pub-id></element-citation></ref><ref id="CR76"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Defer</surname><given-names>N</given-names></name><name><surname>Best-Belpomme</surname><given-names>M</given-names></name><name><surname>Hanoune</surname><given-names>J</given-names></name></person-group><article-title>Tissue specificity and physiological relevance of various isoforms of adenylyl cyclase</article-title><source>Am J Physiol Renal Physiol</source><year>2000</year><volume>279</volume><issue>3</issue><fpage>F400</fpage><lpage>F416</lpage><pub-id pub-id-type="doi">10.1152/ajprenal.2000.279.3.F400</pub-id><?supplied-pmid 10966920?><pub-id pub-id-type="pmid">10966920</pub-id></element-citation></ref><ref id="CR77"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pizzino</surname><given-names>G</given-names></name><name><surname>Irrera</surname><given-names>N</given-names></name><name><surname>Cucinotta</surname><given-names>M</given-names></name><name><surname>Pallio</surname><given-names>G</given-names></name><name><surname>Mannino</surname><given-names>F</given-names></name><name><surname>Arcoraci</surname><given-names>V</given-names></name><name><surname>Squadrito</surname><given-names>F</given-names></name><name><surname>Altavilla</surname><given-names>D</given-names></name><name><surname>Bitto</surname><given-names>A</given-names></name></person-group><article-title>Oxidative stress: harms and benefits for human health</article-title><source>Oxid Med Cell Longev</source><year>2017</year><volume>2017</volume><fpage>8416763</fpage><pub-id pub-id-type="doi">10.1155/2017/8416763</pub-id><?supplied-pmid 28819546?><pub-id pub-id-type="pmid">28819546</pub-id></element-citation></ref><ref id="CR78"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>S-J</given-names></name><name><surname>Kim</surname><given-names>TS</given-names></name><name><surname>Hong</surname><given-names>S</given-names></name><name><surname>Rhim</surname><given-names>H</given-names></name><name><surname>Kim</surname><given-names>IY</given-names></name><name><surname>Kang</surname><given-names>S</given-names></name></person-group><article-title>Oxidative stimuli affect polyglutamine aggregation and cell death in human mutant ataxin-1-expressing cells</article-title><source>Neurosci Lett</source><year>2003</year><volume>348</volume><issue>1</issue><fpage>21</fpage><lpage>24</lpage><pub-id pub-id-type="doi">10.1016/S0304-3940(03)00657-8</pub-id><?supplied-pmid 12893416?><pub-id pub-id-type="pmid">12893416</pub-id></element-citation></ref><ref id="CR79"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xiao</surname><given-names>L</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Yang</surname><given-names>F</given-names></name><name><surname>Huang</surname><given-names>A</given-names></name><name><surname>Deng</surname><given-names>J</given-names></name><name><surname>Liang</surname><given-names>M</given-names></name><name><surname>Ma</surname><given-names>F</given-names></name><name><surname>Hu</surname><given-names>M</given-names></name><name><surname>Huang</surname><given-names>Z</given-names></name></person-group><article-title>Salidroside protects <italic>Caenorhabditis elegans</italic> neurons from polyglutamine-mediated toxicity by reducing oxidative stress</article-title><source>Molecules</source><year>2014</year><volume>19</volume><issue>6</issue><fpage>7757</fpage><lpage>7769</lpage><pub-id pub-id-type="doi">10.3390/molecules19067757</pub-id><?supplied-pmid 24918543?><pub-id pub-id-type="pmid">24918543</pub-id></element-citation></ref><ref id="CR80"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pacheco</surname><given-names>LS</given-names></name><name><surname>da Silveira</surname><given-names>AF</given-names></name><name><surname>Trott</surname><given-names>A</given-names></name><name><surname>Houenou</surname><given-names>LJ</given-names></name><name><surname>Algarve</surname><given-names>TD</given-names></name><name><surname>Bell&#x000f3;</surname><given-names>C</given-names></name><name><surname>Lenz</surname><given-names>AF</given-names></name><name><surname>M&#x000e2;nica-Cattani</surname><given-names>MF</given-names></name><name><surname>da Cruz</surname><given-names>IBM</given-names></name></person-group><article-title>Association between Machado-Joseph disease and oxidative stress biomarkers</article-title><source>Mutat Res</source><year>2013</year><volume>757</volume><issue>2</issue><fpage>99</fpage><lpage>103</lpage><pub-id pub-id-type="doi">10.1016/j.mrgentox.2013.06.023</pub-id><?supplied-pmid 23994570?><pub-id pub-id-type="pmid">23994570</pub-id></element-citation></ref><ref id="CR81"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Giuliano</surname><given-names>P</given-names></name><name><surname>de Cristofaro</surname><given-names>T</given-names></name><name><surname>Affaitati</surname><given-names>A</given-names></name><name><surname>Pizzulo</surname><given-names>GM</given-names></name><name><surname>Feliciello</surname><given-names>A</given-names></name><name><surname>Criscuolo</surname><given-names>C</given-names></name><name><surname>De Michele</surname><given-names>G</given-names></name><name><surname>Filla</surname><given-names>A</given-names></name><name><surname>Avvedimento</surname><given-names>EV</given-names></name><name><surname>Varrone</surname><given-names>S</given-names></name></person-group><article-title>DNA damage induced by polyglutamine-expanded proteins</article-title><source>Hum Mol Genet</source><year>2003</year><volume>12</volume><issue>18</issue><fpage>2301</fpage><lpage>2309</lpage><pub-id pub-id-type="doi">10.1093/hmg/ddg242</pub-id><?supplied-pmid 12915485?><pub-id pub-id-type="pmid">12915485</pub-id></element-citation></ref><ref id="CR82"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bertoni</surname><given-names>A</given-names></name><name><surname>Giuliano</surname><given-names>P</given-names></name><name><surname>Galgani</surname><given-names>M</given-names></name><name><surname>Rotoli</surname><given-names>D</given-names></name><name><surname>Ulianich</surname><given-names>L</given-names></name><name><surname>Adornetto</surname><given-names>A</given-names></name><name><surname>Santillo</surname><given-names>MR</given-names></name><name><surname>Porcellini</surname><given-names>A</given-names></name><name><surname>Avvedimento</surname><given-names>VE</given-names></name></person-group><article-title>Early and late events induced by polyQ-expanded proteins: identification of a common pathogenic property of polyQ-expanded proteins</article-title><source>J Biol Chem</source><year>2011</year><volume>286</volume><issue>6</issue><fpage>4727</fpage><lpage>4741</lpage><pub-id pub-id-type="doi">10.1074/jbc.M110.156521</pub-id><?supplied-pmid 21115499?><pub-id pub-id-type="pmid">21115499</pub-id></element-citation></ref><ref id="CR83"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aquilano</surname><given-names>K</given-names></name><name><surname>Baldelli</surname><given-names>S</given-names></name><name><surname>Pagliei</surname><given-names>B</given-names></name><name><surname>Cannata</surname><given-names>SM</given-names></name><name><surname>Rotilio</surname><given-names>G</given-names></name><name><surname>Ciriolo</surname><given-names>MR</given-names></name></person-group><article-title>p53 orchestrates the PGC-1&#x003b1;-mediated antioxidant response upon mild redox and metabolic imbalance</article-title><source>Antioxid Redox Signal</source><year>2013</year><volume>18</volume><issue>4</issue><fpage>386</fpage><lpage>399</lpage><pub-id pub-id-type="doi">10.1089/ars.2012.4615</pub-id><?supplied-pmid 22861165?><pub-id pub-id-type="pmid">22861165</pub-id></element-citation></ref><ref id="CR84"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jauslin</surname><given-names>ML</given-names></name><name><surname>Vertuani</surname><given-names>S</given-names></name><name><surname>Durini</surname><given-names>E</given-names></name><name><surname>Buzzoni</surname><given-names>L</given-names></name><name><surname>Ciliberti</surname><given-names>N</given-names></name><name><surname>Verdecchia</surname><given-names>S</given-names></name><name><surname>Palozza</surname><given-names>P</given-names></name><name><surname>Meier</surname><given-names>T</given-names></name><name><surname>Manfredini</surname><given-names>S</given-names></name></person-group><article-title>Protective effects of Fe-Aox29, a novel antioxidant derived from a molecular combination of idebenone and vitamin E, in immortalized fibroblasts and fibroblasts from patients with Friedreich ataxia</article-title><source>Mol Cell Biochem</source><year>2007</year><volume>302</volume><issue>1&#x02013;2</issue><fpage>79</fpage><lpage>85</lpage><pub-id pub-id-type="doi">10.1007/s11010-007-9429-2</pub-id><?supplied-pmid 17476463?><pub-id pub-id-type="pmid">17476463</pub-id></element-citation></ref><ref id="CR85"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Piemonte</surname><given-names>F</given-names></name><name><surname>Pastore</surname><given-names>A</given-names></name><name><surname>Tozzi</surname><given-names>G</given-names></name><name><surname>Tagliacozzi</surname><given-names>D</given-names></name><name><surname>Santorelli</surname><given-names>FM</given-names></name><name><surname>Carrozzo</surname><given-names>R</given-names></name><name><surname>Casali</surname><given-names>C</given-names></name><name><surname>Damiano</surname><given-names>M</given-names></name><name><surname>Federici</surname><given-names>G</given-names></name><name><surname>Bertini</surname><given-names>E</given-names></name></person-group><article-title>Glutathione in blood of patients with Friedreich&#x02019;s ataxia</article-title><source>Eur J Clin Invest</source><year>2001</year><volume>31</volume><issue>11</issue><fpage>1007</fpage><lpage>1011</lpage><pub-id pub-id-type="doi">10.1046/j.1365-2362.2001.00922.x</pub-id><?supplied-pmid 11737244?><pub-id pub-id-type="pmid">11737244</pub-id></element-citation></ref><ref id="CR86"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Auch&#x000e8;re</surname><given-names>F</given-names></name><name><surname>Santos</surname><given-names>R</given-names></name><name><surname>Planamente</surname><given-names>S</given-names></name><name><surname>Lesuisse</surname><given-names>E</given-names></name><name><surname>Camadro</surname><given-names>J-M</given-names></name></person-group><article-title>Glutathione-dependent redox status of frataxin-deficient cells in a yeast model of Friedreich&#x02019;s ataxia</article-title><source>Hum Mol Genet</source><year>2008</year><volume>17</volume><issue>18</issue><fpage>2790</fpage><lpage>2802</lpage><pub-id pub-id-type="doi">10.1093/hmg/ddn178</pub-id><?supplied-pmid 18562474?><pub-id pub-id-type="pmid">18562474</pub-id></element-citation></ref><ref id="CR87"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clark</surname><given-names>E</given-names></name><name><surname>Johnson</surname><given-names>J</given-names></name><name><surname>Dong</surname><given-names>YN</given-names></name><name><surname>Mercado-Ayon</surname><given-names>E</given-names></name><name><surname>Warren</surname><given-names>N</given-names></name><name><surname>Zhai</surname><given-names>M</given-names></name><name><surname>McMillan</surname><given-names>E</given-names></name><name><surname>Salovin</surname><given-names>A</given-names></name><name><surname>Lin</surname><given-names>H</given-names></name><name><surname>Lynch</surname><given-names>DR</given-names></name></person-group><article-title>Role of frataxin protein deficiency and metabolic dysfunction in Friedreich ataxia, an autosomal recessive mitochondrial disease. Neuronal</article-title><source>Signal.</source><year>2018</year><volume>2</volume><issue>4</issue><fpage>NS20180060</fpage></element-citation></ref><ref id="CR88"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gomes</surname><given-names>CM</given-names></name><name><surname>Santos</surname><given-names>R</given-names></name></person-group><article-title>Neurodegeneration in Friedreich&#x02019;s ataxia: from defective frataxin to oxidative stress</article-title><source>Oxid Med Cell Longev</source><year>2013</year><volume>2013</volume><fpage>487534</fpage><pub-id pub-id-type="doi">10.1155/2013/487534</pub-id><?supplied-pmid 23936609?><pub-id pub-id-type="pmid">23936609</pub-id></element-citation></ref><ref id="CR89"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anderson</surname><given-names>PR</given-names></name><name><surname>Kirby</surname><given-names>K</given-names></name><name><surname>Orr</surname><given-names>WC</given-names></name><name><surname>Hilliker</surname><given-names>AJ</given-names></name><name><surname>Phillips</surname><given-names>JP</given-names></name></person-group><article-title>Hydrogen peroxide scavenging rescues frataxin deficiency in a <italic>Drosophila</italic> model of Friedreich&#x02019;s ataxia</article-title><source>Proc Natl Acad Sci U S A</source><year>2008</year><volume>105</volume><issue>2</issue><fpage>611</fpage><lpage>616</lpage><pub-id pub-id-type="doi">10.1073/pnas.0709691105</pub-id><?supplied-pmid 18184803?><pub-id pub-id-type="pmid">18184803</pub-id></element-citation></ref><ref id="CR90"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Santos</surname><given-names>R</given-names></name><name><surname>Lefevre</surname><given-names>S</given-names></name><name><surname>Sliwa</surname><given-names>D</given-names></name><name><surname>Seguin</surname><given-names>A</given-names></name><name><surname>Camadro</surname><given-names>J-M</given-names></name><name><surname>Lesuisse</surname><given-names>E</given-names></name></person-group><article-title>Friedreich ataxia: molecular mechanisms, redox considerations, and therapeutic opportunities</article-title><source>Antioxid Redox Signal</source><year>2010</year><volume>13</volume><issue>5</issue><fpage>651</fpage><lpage>690</lpage><pub-id pub-id-type="doi">10.1089/ars.2009.3015</pub-id><?supplied-pmid 20156111?><pub-id pub-id-type="pmid">20156111</pub-id></element-citation></ref><ref id="CR91"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lefevre</surname><given-names>S</given-names></name><name><surname>Brossas</surname><given-names>C</given-names></name><name><surname>Auch&#x000e8;re</surname><given-names>F</given-names></name><name><surname>Boggetto</surname><given-names>N</given-names></name><name><surname>Camadro</surname><given-names>J-M</given-names></name><name><surname>Santos</surname><given-names>R</given-names></name></person-group><article-title>Apn1 AP-endonuclease is essential for the repair of oxidatively damaged DNA bases in yeast frataxin-deficient cells</article-title><source>Hum Mol Genet</source><year>2012</year><volume>21</volume><issue>18</issue><fpage>4060</fpage><lpage>4072</lpage><pub-id pub-id-type="doi">10.1093/hmg/dds230</pub-id><?supplied-pmid 22706278?><pub-id pub-id-type="pmid">22706278</pub-id></element-citation></ref><ref id="CR92"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carletti</surname><given-names>B</given-names></name><name><surname>Piemonte</surname><given-names>F</given-names></name></person-group><article-title>Friedreich&#x02019;s ataxia: a neuronal point of view on the oxidative stress hypothesis</article-title><source>Antioxidants</source><year>2014</year><volume>3</volume><issue>3</issue><fpage>592</fpage><lpage>603</lpage><pub-id pub-id-type="doi">10.3390/antiox3030592</pub-id><?supplied-pmid 26785073?><pub-id pub-id-type="pmid">26785073</pub-id></element-citation></ref><ref id="CR93"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takahashi</surname><given-names>K</given-names></name><name><surname>Tatsunami</surname><given-names>R</given-names></name><name><surname>Oba</surname><given-names>T</given-names></name><name><surname>Tampo</surname><given-names>Y</given-names></name></person-group><article-title>Buthionine sulfoximine promotes methylglyoxal-induced apoptotic cell death and oxidative stress in endothelial cells</article-title><source>Biol Pharm Bull</source><year>2010</year><volume>33</volume><issue>4</issue><fpage>556</fpage><lpage>560</lpage><pub-id pub-id-type="doi">10.1248/bpb.33.556</pub-id><?supplied-pmid 20410585?><pub-id pub-id-type="pmid">20410585</pub-id></element-citation></ref><ref id="CR94"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arruda</surname><given-names>AP</given-names></name><name><surname>Hotamisligil</surname><given-names>GS</given-names></name></person-group><article-title>Calcium homeostasis and organelle function in the pathogenesis of obesity and diabetes</article-title><source>Cell Metab</source><year>2015</year><volume>22</volume><issue>3</issue><fpage>381</fpage><lpage>397</lpage><pub-id pub-id-type="doi">10.1016/j.cmet.2015.06.010</pub-id><?supplied-pmid 26190652?><pub-id pub-id-type="pmid">26190652</pub-id></element-citation></ref><ref id="CR95"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>T-S</given-names></name><name><surname>Tu</surname><given-names>H</given-names></name><name><surname>Chan</surname><given-names>EYW</given-names></name><name><surname>Maximov</surname><given-names>A</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Wellington</surname><given-names>CL</given-names></name><name><surname>Hayden</surname><given-names>MR</given-names></name><name><surname>Bezprozvanny</surname><given-names>I</given-names></name></person-group><article-title>Huntingtin and huntingtin-associated protein 1 influence neuronal calcium signaling mediated by inositol-(1, 4, 5) triphosphate receptor type 1</article-title><source>Neuron</source><year>2003</year><volume>39</volume><issue>2</issue><fpage>227</fpage><lpage>239</lpage><pub-id pub-id-type="doi">10.1016/S0896-6273(03)00366-0</pub-id><?supplied-pmid 12873381?><pub-id pub-id-type="pmid">12873381</pub-id></element-citation></ref><ref id="CR96"><label>96.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>T-S</given-names></name><name><surname>Slow</surname><given-names>E</given-names></name><name><surname>Lupu</surname><given-names>V</given-names></name><name><surname>Stavrovskaya</surname><given-names>IG</given-names></name><name><surname>Sugimori</surname><given-names>M</given-names></name><name><surname>Llin&#x000e1;s</surname><given-names>R</given-names></name><name><surname>Kristal</surname><given-names>BS</given-names></name><name><surname>Hayden</surname><given-names>MR</given-names></name><name><surname>Bezprozvanny</surname><given-names>I</given-names></name></person-group><article-title>Disturbed Ca<sup>2+</sup> signaling and apoptosis of medium spiny neurons in Huntington&#x02019;s disease</article-title><source>Proc Natl Acad Sci U S A</source><year>2005</year><volume>102</volume><issue>7</issue><fpage>2602</fpage><lpage>2607</lpage><pub-id pub-id-type="doi">10.1073/pnas.0409402102</pub-id><?supplied-pmid 15695335?><pub-id pub-id-type="pmid">15695335</pub-id></element-citation></ref><ref id="CR97"><label>97.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koch</surname><given-names>P</given-names></name><name><surname>Breuer</surname><given-names>P</given-names></name><name><surname>Peitz</surname><given-names>M</given-names></name><name><surname>Jungverdorben</surname><given-names>J</given-names></name><name><surname>Kesavan</surname><given-names>J</given-names></name><name><surname>Poppe</surname><given-names>D</given-names></name><name><surname>Doerr</surname><given-names>J</given-names></name><name><surname>Ladewig</surname><given-names>J</given-names></name><name><surname>Mertens</surname><given-names>J</given-names></name><name><surname>T&#x000fc;ting</surname><given-names>T</given-names></name><name><surname>Hoffmann</surname><given-names>P</given-names></name><name><surname>Klockgether</surname><given-names>T</given-names></name><name><surname>Evert</surname><given-names>BO</given-names></name><name><surname>W&#x000fc;llner</surname><given-names>U</given-names></name><name><surname>Br&#x000fc;stle</surname><given-names>O</given-names></name></person-group><article-title>Excitation-induced ataxin-3 aggregation in neurons from patients with Machado-Joseph disease</article-title><source>Nature</source><year>2011</year><volume>480</volume><issue>7378</issue><fpage>543</fpage><lpage>546</lpage><pub-id pub-id-type="doi">10.1038/nature10671</pub-id><?supplied-pmid 22113611?><pub-id pub-id-type="pmid">22113611</pub-id></element-citation></ref><ref id="CR98"><label>98.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Egorova</surname><given-names>P</given-names></name><name><surname>Popugaeva</surname><given-names>E</given-names></name><name><surname>Bezprozvanny</surname><given-names>I</given-names></name></person-group><article-title>Disturbed calcium signaling in spinocerebellar ataxias and Alzheimer&#x02019;s disease</article-title><source>Semin Cell Dev Biol</source><year>2015</year><volume>40</volume><fpage>127</fpage><lpage>133</lpage><pub-id pub-id-type="doi">10.1016/j.semcdb.2015.03.010</pub-id><?supplied-pmid 25846864?><pub-id pub-id-type="pmid">25846864</pub-id></element-citation></ref><ref id="CR99"><label>99.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barski</surname><given-names>JJ</given-names></name><name><surname>Hartmann</surname><given-names>J</given-names></name><name><surname>Rose</surname><given-names>CR</given-names></name><name><surname>Hoebeek</surname><given-names>F</given-names></name><name><surname>M&#x000f6;rl</surname><given-names>K</given-names></name><name><surname>Noll-Hussong</surname><given-names>M</given-names></name><name><surname>De Zeeuw</surname><given-names>CI</given-names></name><name><surname>Konnerth</surname><given-names>A</given-names></name><name><surname>Meyer</surname><given-names>M</given-names></name></person-group><article-title>Calbindin in cerebellar Purkinje cells is a critical determinant of the precision of motor coordination</article-title><source>J Neurosci</source><year>2003</year><volume>23</volume><issue>8</issue><fpage>3469</fpage><lpage>3477</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.23-08-03469.2003</pub-id><?supplied-pmid 12716955?><pub-id pub-id-type="pmid">12716955</pub-id></element-citation></ref><ref id="CR100"><label>100.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schmidt</surname><given-names>H</given-names></name></person-group><article-title>Three functional facets of calbindin D-28k</article-title><source>Front Mol Neurosci</source><year>2012</year><volume>5</volume><fpage>25</fpage><pub-id pub-id-type="doi">10.3389/fnmol.2012.00025</pub-id><?supplied-pmid 22435048?><pub-id pub-id-type="pmid">22435048</pub-id></element-citation></ref><ref id="CR101"><label>101.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>C-J</given-names></name><name><surname>Seo</surname><given-names>Y-S</given-names></name></person-group><article-title>Heat shock proteins: a review of the molecular chaperones for plant immunity</article-title><source>Plant Pathol J</source><year>2015</year><volume>31</volume><issue>4</issue><fpage>323</fpage><lpage>333</lpage><pub-id pub-id-type="doi">10.5423/PPJ.RW.08.2015.0150</pub-id><?supplied-pmid 26676169?><pub-id pub-id-type="pmid">26676169</pub-id></element-citation></ref><ref id="CR102"><label>102.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miller</surname><given-names>DJ</given-names></name><name><surname>Fort</surname><given-names>PE</given-names></name></person-group><article-title>Heat shock proteins regulatory role in neurodevelopment</article-title><source>Front Neurosci</source><year>2018</year><volume>12</volume><fpage>821</fpage><pub-id pub-id-type="doi">10.3389/fnins.2018.00821</pub-id><?supplied-pmid 30483047?><pub-id pub-id-type="pmid">30483047</pub-id></element-citation></ref><ref id="CR103"><label>103.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>C-M</given-names></name><name><surname>Lee</surname><given-names>L-C</given-names></name><name><surname>Soong</surname><given-names>B-W</given-names></name><name><surname>Fung</surname><given-names>H-C</given-names></name><name><surname>Hsu</surname><given-names>W-C</given-names></name><name><surname>Lin</surname><given-names>P-Y</given-names></name><name><surname>Huang</surname><given-names>H-J</given-names></name><name><surname>Chen</surname><given-names>F-L</given-names></name><name><surname>Lin</surname><given-names>C-Y</given-names></name><name><surname>Lee-Chen</surname><given-names>G-J</given-names></name><name><surname>Wu</surname><given-names>Y-R</given-names></name></person-group><article-title>SCA17 repeat expansion: mildly expanded CAG/CAA repeat alleles in neurological disorders and the functional implications</article-title><source>Clin Chim Acta</source><year>2010</year><volume>411</volume><issue>5&#x02013;6</issue><fpage>375</fpage><lpage>380</lpage><pub-id pub-id-type="doi">10.1016/j.cca.2009.12.002</pub-id><?supplied-pmid 20004653?><pub-id pub-id-type="pmid">20004653</pub-id></element-citation></ref><ref id="CR104"><label>104.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>L-C</given-names></name><name><surname>Chen</surname><given-names>C-M</given-names></name><name><surname>Wang</surname><given-names>H-C</given-names></name><name><surname>Hsieh</surname><given-names>H-H</given-names></name><name><surname>Chiu</surname><given-names>I-S</given-names></name><name><surname>Su</surname><given-names>M-T</given-names></name><name><surname>Hsieh-Li</surname><given-names>H-M</given-names></name><name><surname>Wu</surname><given-names>C-H</given-names></name><name><surname>Lee</surname><given-names>G-C</given-names></name><name><surname>Lee-Chen</surname><given-names>G-J</given-names></name><name><surname>Lin</surname><given-names>J-Y</given-names></name></person-group><article-title>Role of the CCAAT-binding protein NFY in SCA17 pathogenesis</article-title><source>PLoS ONE</source><year>2012</year><volume>7</volume><issue>4</issue><fpage>e35302</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0035302</pub-id><?supplied-pmid 22530004?><pub-id pub-id-type="pmid">22530004</pub-id></element-citation></ref><ref id="CR105"><label>105.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cummings</surname><given-names>CJ</given-names></name><name><surname>Sun</surname><given-names>Y</given-names></name><name><surname>Opal</surname><given-names>P</given-names></name><name><surname>Antalffy</surname><given-names>B</given-names></name><name><surname>Mestril</surname><given-names>R</given-names></name><name><surname>Orr</surname><given-names>HT</given-names></name><name><surname>Dillmann</surname><given-names>WH</given-names></name><name><surname>Zoghbi</surname><given-names>HY</given-names></name></person-group><article-title>Over-expression of inducible HSP70 chaperone suppresses neuropathology and improves motor function in SCA1 mice</article-title><source>Hum Mol Genet</source><year>2001</year><volume>10</volume><issue>14</issue><fpage>1511</fpage><lpage>1518</lpage><pub-id pub-id-type="doi">10.1093/hmg/10.14.1511</pub-id><?supplied-pmid 11448943?><pub-id pub-id-type="pmid">11448943</pub-id></element-citation></ref><ref id="CR106"><label>106.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wyttenbach</surname><given-names>A</given-names></name><name><surname>Sauvageot</surname><given-names>O</given-names></name><name><surname>Carmichael</surname><given-names>J</given-names></name><name><surname>Diaz-Latoud</surname><given-names>C</given-names></name><name><surname>Arrigo</surname><given-names>A-P</given-names></name><name><surname>Rubinsztein</surname><given-names>DC</given-names></name></person-group><article-title>Heat shock protein 27 prevents cellular polyglutamine toxicity and suppresses the increase of reactive oxygen species caused by huntingtin</article-title><source>Hum Mol Genet</source><year>2002</year><volume>11</volume><issue>9</issue><fpage>1137</fpage><lpage>1151</lpage><pub-id pub-id-type="doi">10.1093/hmg/11.9.1137</pub-id><?supplied-pmid 11978772?><pub-id pub-id-type="pmid">11978772</pub-id></element-citation></ref><ref id="CR107"><label>107.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fujimoto</surname><given-names>M</given-names></name><name><surname>Takaki</surname><given-names>E</given-names></name><name><surname>Hayashi</surname><given-names>T</given-names></name><name><surname>Kitaura</surname><given-names>Y</given-names></name><name><surname>Tanaka</surname><given-names>Y</given-names></name><name><surname>Inouye</surname><given-names>S</given-names></name><name><surname>Nakai</surname><given-names>A</given-names></name></person-group><article-title>Active HSF1 significantly suppresses polyglutamine aggregate formation in cellular and mouse models</article-title><source>J Biol Chem</source><year>2005</year><volume>280</volume><issue>41</issue><fpage>34908</fpage><lpage>34916</lpage><pub-id pub-id-type="doi">10.1074/jbc.M506288200</pub-id><?supplied-pmid 16051598?><pub-id pub-id-type="pmid">16051598</pub-id></element-citation></ref><ref id="CR108"><label>108.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fujikake</surname><given-names>N</given-names></name><name><surname>Nagai</surname><given-names>Y</given-names></name><name><surname>Popiel</surname><given-names>HA</given-names></name><name><surname>Okamoto</surname><given-names>Y</given-names></name><name><surname>Yamaguchi</surname><given-names>M</given-names></name><name><surname>Toda</surname><given-names>T</given-names></name></person-group><article-title>Heat shock transcription factor 1-activating compounds suppress polyglutamine-induced neurodegeneration through induction of multiple molecular chaperones</article-title><source>J Biol Chem</source><year>2008</year><volume>283</volume><issue>38</issue><fpage>26188</fpage><lpage>26197</lpage><pub-id pub-id-type="doi">10.1074/jbc.M710521200</pub-id><?supplied-pmid 18632670?><pub-id pub-id-type="pmid">18632670</pub-id></element-citation></ref><ref id="CR109"><label>109.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kuo</surname><given-names>Y</given-names></name><name><surname>Ren</surname><given-names>S</given-names></name><name><surname>Lao</surname><given-names>U</given-names></name><name><surname>Edgar</surname><given-names>BA</given-names></name><name><surname>Wang</surname><given-names>T</given-names></name></person-group><article-title>Suppression of polyglutamine protein toxicity by co-expression of a heat-shock protein 40 and a heat-shock protein 110</article-title><source>Cell Death Dis</source><year>2013</year><volume>4</volume><issue>10</issue><fpage>e833</fpage><pub-id pub-id-type="doi">10.1038/cddis.2013.351</pub-id><?supplied-pmid 24091676?><pub-id pub-id-type="pmid">24091676</pub-id></element-citation></ref><ref id="CR110"><label>110.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beutler</surname><given-names>JA</given-names></name></person-group><article-title>Natural products as a foundation for drug discovery</article-title><source>Curr Protoc Pharmacol.</source><year>2019</year><volume>86</volume><issue>1</issue><fpage>e67</fpage><?supplied-pmid 31539923?><pub-id pub-id-type="pmid">31539923</pub-id></element-citation></ref><ref id="CR111"><label>111.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Krause</surname><given-names>J</given-names></name><name><surname>Tobin</surname><given-names>G</given-names></name></person-group><person-group person-group-type="editor"><name><surname>Kulka</surname><given-names>M</given-names></name></person-group><article-title>Discovery, development, and regulation of natural products</article-title><source>Using old solutions to new problems-natural drug discovery in the 21st century</source><year>2013</year><publisher-loc>London</publisher-loc><publisher-name>IntechOpen</publisher-name><fpage>1</fpage><lpage>35</lpage></element-citation></ref><ref id="CR112"><label>112.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Atanasov</surname><given-names>AG</given-names></name><name><surname>Waltenberger</surname><given-names>B</given-names></name><name><surname>Pferschy-Wenzig</surname><given-names>E-M</given-names></name><name><surname>Linder</surname><given-names>T</given-names></name><name><surname>Wawrosch</surname><given-names>C</given-names></name><name><surname>Uhrin</surname><given-names>P</given-names></name><name><surname>Temml</surname><given-names>V</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Schwaiger</surname><given-names>S</given-names></name><name><surname>Heiss</surname><given-names>EH</given-names></name><name><surname>Rollinger</surname><given-names>JM</given-names></name></person-group><article-title>Discovery and resupply of pharmacologically active plant-derived natural products: a review</article-title><source>Biotechnol Adv</source><year>2015</year><volume>33</volume><issue>8</issue><fpage>1582</fpage><lpage>1614</lpage><pub-id pub-id-type="doi">10.1016/j.biotechadv.2015.08.001</pub-id><?supplied-pmid 26281720?><pub-id pub-id-type="pmid">26281720</pub-id></element-citation></ref><ref id="CR113"><label>113.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Canter</surname><given-names>PH</given-names></name><name><surname>Thomas</surname><given-names>H</given-names></name><name><surname>Ernst</surname><given-names>E</given-names></name></person-group><article-title>Bringing medicinal plants into cultivation: opportunities and challenges for biotechnology</article-title><source>Trends Biotechnol</source><year>2005</year><volume>23</volume><issue>4</issue><fpage>180</fpage><lpage>185</lpage><pub-id pub-id-type="doi">10.1016/j.tibtech.2005.02.002</pub-id><?supplied-pmid 15780709?><pub-id pub-id-type="pmid">15780709</pub-id></element-citation></ref><ref id="CR114"><label>114.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perdomini</surname><given-names>M</given-names></name><name><surname>Hick</surname><given-names>A</given-names></name><name><surname>Puccio</surname><given-names>H</given-names></name><name><surname>Pook</surname><given-names>MA</given-names></name></person-group><article-title>Animal and cellular models of Friedreich ataxia</article-title><source>J Neurochem</source><year>2013</year><volume>126</volume><issue>Suppl 1</issue><fpage>65</fpage><lpage>79</lpage><pub-id pub-id-type="doi">10.1111/jnc.12219</pub-id><?supplied-pmid 23859342?><pub-id pub-id-type="pmid">23859342</pub-id></element-citation></ref><ref id="CR115"><label>115.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matos</surname><given-names>CA</given-names></name><name><surname>de Almeida</surname><given-names>LP</given-names></name><name><surname>N&#x000f3;brega</surname><given-names>C</given-names></name></person-group><article-title>Machado-Joseph disease/spinocerebellar ataxia type 3: lessons from disease pathogenesis and clues into therapy</article-title><source>J Neurochem</source><year>2019</year><volume>148</volume><issue>1</issue><fpage>8</fpage><lpage>28</lpage><pub-id pub-id-type="doi">10.1111/jnc.14541</pub-id><?supplied-pmid 29959858?><pub-id pub-id-type="pmid">29959858</pub-id></element-citation></ref><ref id="CR116"><label>116.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cendelin</surname><given-names>J</given-names></name></person-group><article-title>From mice to men: lessons from mutant ataxic mice</article-title><source>Cerebellum Ataxias</source><year>2014</year><volume>1</volume><fpage>4</fpage><pub-id pub-id-type="doi">10.1186/2053-8871-1-4</pub-id><?supplied-pmid 26331028?><pub-id pub-id-type="pmid">26331028</pub-id></element-citation></ref><ref id="CR117"><label>117.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Faber</surname><given-names>J</given-names></name><name><surname>Fonseca</surname><given-names>LM</given-names></name></person-group><article-title>How sample size influences research outcomes</article-title><source>Dental Press J Orthod</source><year>2014</year><volume>19</volume><issue>4</issue><fpage>27</fpage><lpage>29</lpage><pub-id pub-id-type="doi">10.1590/2176-9451.19.4.027-029.ebo</pub-id><?supplied-pmid 25279518?><pub-id pub-id-type="pmid">25279518</pub-id></element-citation></ref><ref id="CR118"><label>118.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hughes</surname><given-names>JP</given-names></name><name><surname>Rees</surname><given-names>S</given-names></name><name><surname>Kalindjian</surname><given-names>SB</given-names></name><name><surname>Philpott</surname><given-names>KL</given-names></name></person-group><article-title>Principles of early drug discovery</article-title><source>Br J Pharmacol</source><year>2011</year><volume>162</volume><issue>6</issue><fpage>1239</fpage><lpage>1249</lpage><pub-id pub-id-type="doi">10.1111/j.1476-5381.2010.01127.x</pub-id><?supplied-pmid 21091654?><pub-id pub-id-type="pmid">21091654</pub-id></element-citation></ref><ref id="CR119"><label>119.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Keum</surname><given-names>J</given-names></name><name><surname>Yoo</surname><given-names>S</given-names></name><name><surname>Lee</surname><given-names>D</given-names></name><name><surname>Nam</surname><given-names>H</given-names></name></person-group><article-title>Prediction of compound-target interactions of natural products using large-scale drug and protein information</article-title><source>BMC Bioinformatics</source><year>2016</year><volume>17</volume><issue>Suppl 6</issue><fpage>219</fpage><pub-id pub-id-type="doi">10.1186/s12859-016-1081-y</pub-id><?supplied-pmid 27490208?><pub-id pub-id-type="pmid">27490208</pub-id></element-citation></ref><ref id="CR120"><label>120.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Law</surname><given-names>BYK</given-names></name><name><surname>Wu</surname><given-names>AG</given-names></name><name><surname>Wang</surname><given-names>MJ</given-names></name><name><surname>Zhu</surname><given-names>YZ</given-names></name></person-group><article-title>Chinese medicine: a hope for neurodegenerative diseases?</article-title><source>J Alzheimers Dis</source><year>2017</year><volume>60</volume><issue>s1</issue><fpage>S151</fpage><lpage>S160</lpage><pub-id pub-id-type="doi">10.3233/JAD-170374</pub-id><?supplied-pmid 28671133?><pub-id pub-id-type="pmid">28671133</pub-id></element-citation></ref><ref id="CR121"><label>121.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karczewski</surname><given-names>KJ</given-names></name><name><surname>Snyder</surname><given-names>MP</given-names></name></person-group><article-title>Integrative omics for health and disease</article-title><source>Nat Rev Genet</source><year>2018</year><volume>19</volume><issue>5</issue><fpage>299</fpage><lpage>310</lpage><pub-id pub-id-type="doi">10.1038/nrg.2018.4</pub-id><?supplied-pmid 29479082?><pub-id pub-id-type="pmid">29479082</pub-id></element-citation></ref><ref id="CR122"><label>122.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Woollard</surname><given-names>PM</given-names></name><name><surname>Mehta</surname><given-names>NAL</given-names></name><name><surname>Vamathevan</surname><given-names>JJ</given-names></name><name><surname>Van Horn</surname><given-names>S</given-names></name><name><surname>Bonde</surname><given-names>BK</given-names></name><name><surname>Dow</surname><given-names>DJ</given-names></name></person-group><article-title>The application of next-generation sequencing technologies to drug discovery and development</article-title><source>Drug Discov Today</source><year>2011</year><volume>16</volume><issue>11&#x02013;12</issue><fpage>512</fpage><lpage>519</lpage><pub-id pub-id-type="doi">10.1016/j.drudis.2011.03.006</pub-id><?supplied-pmid 21440664?><pub-id pub-id-type="pmid">21440664</pub-id></element-citation></ref></ref-list></back></article>